[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 698
1. Corti M, Carolis LD, Solari R, Villafañe MF, Schtirbu R, Lewi D, Narbaitz M: Non Hodgkin's lymphoma with cutaneous involvement in AIDS patients: report of five cases and review of the literature. Braz J Infect Dis; 2010 Jan-Feb;14(1):81-5
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non Hodgkin's lymphoma with cutaneous involvement in AIDS patients: report of five cases and review of the literature.
  • Cutaneous B cell lymphoma (CBCL) is a lymphoproliferative disorder of neoplastic B cell of the skin with a wide range of clinical manifestations.
  • Commonly, the clinical features of CBCL are plaques, nodules, or ulcerative lesions.
  • Skin is one of the common sites for extra-nodal lymphomas in patients with AIDS and B cell type is less common than T cell type.
  • Only recently, the existence of B cell lymphomas presenting clinically in the skin without evidence of extra-cutaneous involvement has been accepted as primary CBCL.
  • Here, we are presenting 5 patients with cutaneous involvement in the setting of HIV/AIDS disease.
  • Two of them were primary cutaneous non-Hodgkin lymphomas.
  • All were CBCL; 3 were immunoblastic, 1 was plasmablastic, and the other was a Burkitt lymphoma.
  • [MeSH-major] Lymphoma, AIDS-Related / diagnosis. Skin Neoplasms / diagnosis

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20428660.001).
  • [ISSN] 1678-4391
  • [Journal-full-title] The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases
  • [ISO-abbreviation] Braz J Infect Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


2. Buckstein R, Kerbel RS, Shaked Y, Nayar R, Foden C, Turner R, Lee CR, Taylor D, Zhang L, Man S, Baruchel S, Stempak D, Bertolini F, Crump M: High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma. Clin Cancer Res; 2006 Sep 1;12(17):5190-8
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma.
  • PURPOSE: Angiogenesis is increased in aggressive histology non-Hodgkin's lymphoma and may be a target with selective cyclooxygenase-2 inhibition and metronomic chemotherapy.
  • EXPERIMENTAL DESIGN: We assessed response, toxicity, and biomarkers of angiogenesis to low-dose cyclophosphamide (50 mg p.o. o.d.) and high-dose celecoxib (400 mg p.o. b.i.d.) in adult patients with relapsed or refractory aggressive non-Hodgkin's lymphoma in a multicenter phase II prospective study.
  • Patients had primarily relapsed diffuse large B-cell lymphoma (63%) were heavily pretreated (median of three regimens) and high risk (79% international prognostic index, >or=2) and 34% were relapsed after autologous stem cell transplant.
  • The most common toxicity was skin rash (40%); myelosuppression and gastrointestinal side effects were uncommon.
  • CONCLUSIONS: Low-dose cyclophosphamide and high-dose celecoxib is well tolerated and active in pretreated aggressive non-Hodgkin's lymphoma.
  • [MeSH-major] Cyclophosphamide / administration & dosage. Lymphoma, Non-Hodgkin / drug therapy. Pyrazoles / administration & dosage. Sulfonamides / administration & dosage

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CELECOXIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16951238.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Pyrazoles; 0 / Sulfonamides; 0 / Vascular Endothelial Growth Factor A; 8N3DW7272P / Cyclophosphamide; JCX84Q7J1L / Celecoxib
  •  go-up   go-down


3. Jensen AØ, Thomsen HF, Engebjerg MC, Olesen AB, Friis S, Karagas MR, Sørensen HT: Use of oral glucocorticoids and risk of skin cancer and non-Hodgkin's lymphoma: a population-based case-control study. Br J Cancer; 2009 Jan 13;100(1):200-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of oral glucocorticoids and risk of skin cancer and non-Hodgkin's lymphoma: a population-based case-control study.
  • In North Jutland County, Denmark, we investigated whether use of oral glucocorticoids was associated with an increased risk of developing basal cell carcinoma (BCC), squamous cell carcinoma (SCC), malignant melanoma (MM), and non-Hodgkin's lymphoma (NHL).

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Steroids.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Detect Prev. 2007;31(5):352-8 [18031945.001]
  • [Cites] Arthritis Rheum. 2006 Mar;54(3):692-701 [16508929.001]
  • [Cites] BMJ. 2008 Apr 12;336(7648):813-6 [18334527.001]
  • [Cites] Science. 2000 Mar 31;287(5462):2398-9 [10766613.001]
  • [Cites] Br J Cancer. 2001 Sep 1;85(5):683-6 [11531252.001]
  • [Cites] Transplant Proc. 2003 Aug;35(5):1714-6 [12962768.001]
  • [Cites] J Natl Cancer Inst. 2004 May 5;96(9):709-11 [15126608.001]
  • [Cites] J Natl Cancer Inst. 1988 Oct 5;80(15):1198-202 [3047407.001]
  • [Cites] Am J Epidemiol. 1992 May 1;135(9):1019-28 [1595688.001]
  • [Cites] J Autoimmun. 1992 Apr;5 Suppl A:363-71 [1503633.001]
  • [Cites] WHO Reg Publ Eur Ser. 1993;45:1-4 [8442841.001]
  • [Cites] Ann Epidemiol. 1993 Jan;3(1):111-2 [8287145.001]
  • [Cites] Ugeskr Laeger. 1996 Dec 9;158(50):7202 [9012031.001]
  • [Cites] Lancet. 1997 Feb 8;349(9049):398 [9033469.001]
  • [Cites] Dan Med Bull. 1997 Sep;44(4):445-8 [9377907.001]
  • [Cites] Dan Med Bull. 1997 Nov;44(5):535-9 [9408738.001]
  • [Cites] Am Fam Physician. 1998 Aug;58(2):443-50 [9713398.001]
  • [Cites] J Am Acad Dermatol. 1999 Feb;40(2 Pt 1):177-86 [10025742.001]
  • [Cites] Br J Dermatol. 1999 Feb;140(2):237-42 [10233215.001]
  • [Cites] Dan Med Bull. 1999 Jun;46(3):263-8 [10421985.001]
  • [Cites] Lancet. 1949 Dec 17;2(6590):1134 [15396965.001]
  • [Cites] Ann Rheum Dis. 2005 Dec;64(12):1765-8 [15843445.001]
  • [Cites] Int J Epidemiol. 2005 Dec;34(6):1370-6 [16172102.001]
  • [Cites] J Invest Dermatol. 2008 Apr;128(4):926-31 [17914446.001]
  • (PMID = 19034275.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA057494; United States / NCI NIH HHS / CA / R01 CA57494
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Glucocorticoids
  • [Other-IDs] NLM/ PMC2634665
  •  go-up   go-down


Advertisement
4. Visser JC, Smeekens S, Rommelse N, Verkes RJ, van der Gaag RJ, Buitelaar JK: Assessment of psychopathology in 2- to 5-year-olds: Applying the Infant-Toddler Social Emotional Assessment. Infant Ment Health J; 2010 Nov;31(6):611-629

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The fathers and mothers of 85 children (23.2% girls; age 15-57 months) with autism spectrum, externalizing, or internalizing disorders completed the ITSEA, the Child Behavior Checklist (CBCL/2-3 and 4-18 versions), and the child domain of the Parenting Stress Index (PSI).
  • The ITSEA showed good interrater reliability between parents, and validity was supported by significant correlations with corresponding CBCl and PSI domains.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Michigan Association for Infant Mental Health.
  • (PMID = 28543063.001).
  • [ISSN] 1097-0355
  • [Journal-full-title] Infant mental health journal
  • [ISO-abbreviation] Infant Ment Health J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Dobrinja C, Trevisan G, Liguori G: Primary bilateral adrenal non-Hodgkin's Burkitt-like lymphoma: a rare cause of primary adrenal insufficiency. Case report and literature review. Tumori; 2007 Nov-Dec;93(6):625-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary bilateral adrenal non-Hodgkin's Burkitt-like lymphoma: a rare cause of primary adrenal insufficiency. Case report and literature review.
  • AIMS AND BACKGROUND: Primary bilateral adrenal non-Hodgkin's lymphoma is an extremely rare entity.
  • The most common presenting symptoms are abdominal pain, fever, asthenia, constipation, weight loss or typical symptoms of adrenal insufficiency, hypertension, darkening of skin, orthostatic hypotension or an addisonian crisis.
  • METHODS: The case is presented of a 57-year-old man suffering from primary bilateral adrenal lymphoma with symptoms of adrenal insufficiency syndrome associated with bilateral, stabbing lumbar pain and a palpable mass on the left side.
  • A CT-guided fine needle aspiration biopsy revealed a large B-cell non-Hodgkin's lymphoma.
  • CONCLUSIONS: Primary bilateral adrenal non-Hodgkin's lymphoma mainly affects adult men.
  • [MeSH-major] Adrenal Gland Neoplasms / complications. Adrenal Gland Neoplasms / diagnosis. Adrenal Insufficiency / diagnosis. Adrenal Insufficiency / etiology. Lymphoma, B-Cell / complications. Lymphoma, B-Cell / diagnosis

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. Corticotropin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18338503.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9002-60-2 / Adrenocorticotropic Hormone; EC 1.1.1.27 / L-Lactate Dehydrogenase; VB0R961HZT / Prednisone; CHOP protocol
  • [Number-of-references] 47
  •  go-up   go-down


6. Gelfand JM, Shin DB, Neimann AL, Wang X, Margolis DJ, Troxel AB: The risk of lymphoma in patients with psoriasis. J Invest Dermatol; 2006 Oct;126(10):2194-201
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The risk of lymphoma in patients with psoriasis.
  • Psoriasis has been hypothesized to be associated with an increased risk of lymphoma due to its pathophysiology, its treatments, or a combination of these factors.
  • We performed a large population-based cohort study of the risk of lymphoma in psoriasis patients using the General Practice Research Database.
  • For mild and severe psoriasis patients, the respective adjusted relative risks for lymphoma and its subtypes were as follows: all lymphoma 1.34 (1.16, 1.54) and 1.59 (0.88, 2.89); non-Hodgkin's lymphoma 1.15 (0.97, 1.37) and 0.73 (0.28, 1.96); Hodgkin's lymphoma (HL) 1.42 (1.00, 2.02) and 3.18 (1.01, 9.97); cutaneous T-cell lymphoma (TCL) 4.10 (2.70, 6.23) and 10.75 (3.89, 29.76).
  • Psoriasis is associated with an increased risk of lymphoma.
  • The excess risk of lymphoma attributed to psoriasis was 7.9/100,000 psoriasis patients per year.
  • Although patients with psoriasis have an increased relative risk of lymphoma, the absolute risk attributable to psoriasis is low given that lymphoma is a rare disease and the magnitude of association is modest.
  • [MeSH-major] Lymphoma / etiology. Psoriasis / complications
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Lymphoma, T-Cell, Cutaneous / etiology. Male. Middle Aged. Retrospective Studies. Risk. Skin Neoplasms / etiology

  • Genetic Alliance. consumer health - Psoriasis.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Psoriasis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16741509.001).
  • [ISSN] 0022-202X
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / K23AR051125-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


7. Miyagaki T, Sugaya M, Fujita H, Ohmatsu H, Kakinuma T, Kadono T, Tamaki K, Sato S: Eotaxins and CCR3 interaction regulates the Th2 environment of cutaneous T-cell lymphoma. J Invest Dermatol; 2010 Sep;130(9):2304-11
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eotaxins and CCR3 interaction regulates the Th2 environment of cutaneous T-cell lymphoma.
  • In Hodgkin's disease, eotaxin-1 secreted by fibroblasts collects Th2 cells and eosinophils within the tissue.
  • Similarly, many Th2 cells infiltrate the lesional skin of cutaneous T-cell lymphoma (CTCL).
  • We revealed that fibroblasts from lesional skin of CTCL expressed higher amounts of eotaxin-3 messenger RNA (mRNA) compared with those from normal skin.
  • Lesional skin of CTCL at advanced stages contained significantly higher levels of eotaxin-3 and CCR3 mRNA, compared with early stages of CTCL.
  • Immunohistochemistry revealed that keratinocytes, endothelial cells, and dermal fibroblasts in lesional skin of CTCL showed a stronger expression of eotaxin-3 than did normal skin.
  • [MeSH-major] Chemokine CCL11 / metabolism. Chemokines, CC / metabolism. Lymphoma, T-Cell / metabolism. Receptors, CCR3 / metabolism. Skin Neoplasms / metabolism

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20505746.001).
  • [ISSN] 1523-1747
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCL11 protein, human; 0 / CCL26 protein, human; 0 / CCR3 protein, human; 0 / Chemokine CCL11; 0 / Chemokines, CC; 0 / IL4 protein, human; 0 / RNA, Messenger; 0 / Receptors, CCR3; 0 / Receptors, Interleukin-2; 207137-56-2 / Interleukin-4
  •  go-up   go-down


8. Gleason MM, Zeanah CH, Dickstein S: Recognizing young children in need of mental health assessment: Development and preliminary validity of the early childhood screening assessment. Infant Ment Health J; 2010 May;31(3):335-357

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Early Childhood Screening Assessment (ECSA) is a primary care screening measure developed to identify very young children (1½-5 years old) who need further emotional or behavioral assessment.
  • The ECSA was developed specifically to meet the logistical constraints of primary care settings.
  • In the study, 309 mothers in two primary care clinics completed the ECSA and the Child Behavior Checklist (CBCL; T.
  • ECSA score correlated significantly and strongly with the CBCL Total Problem T score (Spearman's rho = 0.86, p ⩽ .01).
  • It shows potential as a feasible and psychometrically strong tool for busy primary care providers to identify preschoolers who need further socioemotional assessment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Michigan Association for Infant Mental Health.
  • (PMID = 28543224.001).
  • [ISSN] 1097-0355
  • [Journal-full-title] Infant mental health journal
  • [ISO-abbreviation] Infant Ment Health J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Briggs-Gowan MJ, Carter AS: Applying the Infant-Toddler Social & Emotional Assessment (ITSEA) and Brief-ITSEA in early intervention. Infant Ment Health J; 2007 Nov;28(6):564-583

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A sociodemographically diverse sample of 192 parents of 11- to 36-month-old children referred to early intervention programs completed surveys containing the ITSEA, BITSEA, and Child Behavior Checklist (CBCL).
  • Supporting validity, ITSEA and BITSEA problem scores correlated significantly with CBCL Internalizing and Externalizing scores (rs=.28 to .78), as well as with observational ratings of problem behaviors on constructs paralleling the ITSEA domains (rs=.21 to .45).
  • In contrast, ITSEA Competence and BITSEA Competence demonstrated moderate negative associations with CBCL scores (rs=-.39 to -.43).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2007 Michigan Association for Infant Mental Health.
  • (PMID = 28640493.001).
  • [ISSN] 1097-0355
  • [Journal-full-title] Infant mental health journal
  • [ISO-abbreviation] Infant Ment Health J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Kollár B, Rajnics P, Hunyady B, Zeleznik E, Jakucs J, Egyed M: [Primary gastrointestinal non-Hodgkin's lymphoma in two Hungarian regions]. Orv Hetil; 2009 Aug 30;150(35):1649-53
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary gastrointestinal non-Hodgkin's lymphoma in two Hungarian regions].
  • [Transliterated title] Pimer gastrointestinalis non-Hodgkin-lymphoma két magyarországi régió beteganyaga alapján.
  • Over the past few decades, the occurrence of adult onset non-Hodgkin's lymphoma has significantly increased.
  • In addition to the most typical nodal involvement, extra-nodal manifestations are also frequent, affecting, most often, the gastrointestinal tract, the central nervous system and the skin.
  • The treatment strategy for non-Hodgkin's lymphoma has changed over the past decade: chemo-immunotherapy has largely taken over surgical intervention, the dominant treatment option of the past.
  • METHODS: The authors present their experience with 48 patients with non-Hodgkin's lymphoma, affecting the gastrointestinal tract, treated in Kaposvár, in the Kaposi Mór Teaching Hospital and in Gyula, in the Pándy Kálmán County Hospital.
  • RESULTS: The most frequently involved GI organ was the stomach ( n = 26), with the dominant histological type of diffuse large B-cell lymphoma.
  • Patients with upper gastrointestinal tract involvement carried the best prognosis (IPI: 2.0); at the same time, patients with stomach lymphoma achieved the highest rate of remission (73%).
  • CONCLUSIONS: With chemo-immunotherapy the chances of a complete remission have significantly improved over the past decade, thus a significant portion of non-Hodgkin's lymphomas involving the gastrointestinal tract can be cured.
  • IPI index represents the most recognised indicator for assessing the prognosis of non-Hodgkin's lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gastrointestinal Neoplasms / epidemiology. Gastrointestinal Neoplasms / therapy. Immunotherapy. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Female. Humans. Hungary / epidemiology. Incidence. Lymphoma, Large B-Cell, Diffuse / epidemiology. Lymphoma, Large B-Cell, Diffuse / therapy. Male. Middle Aged. Prognosis. Radiotherapy, Adjuvant. Remission Induction. Retrospective Studies. Risk Assessment. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19692309.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


11. Vergine M, Martino G, Santucci E, Cardarelli A, Palmieri A, La Gumina G, Macrina N, Pasta V: [Cutaneous B-cell non-Hodgkin lymphoma: clinical aspects, diagnostic and surgical approach]. G Chir; 2008 Jun-Jul;29(6-7):281-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cutaneous B-cell non-Hodgkin lymphoma: clinical aspects, diagnostic and surgical approach].
  • [Transliterated title] Linfoma cutaneo non Hodgkin a immunofenotipo B: clinica, orientamento diagnostico e chirurgico.
  • By clinical observation and surgical treatment of a patient with cutaneous B-cell non-Hodgkin lymphoma, the Authors describe the nosological approach, the correct diagnosis and the surgical treatment in this disease.
  • [MeSH-major] Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / surgery. Skin Neoplasms / diagnosis. Skin Neoplasms / surgery

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18544265.001).
  • [ISSN] 0391-9005
  • [Journal-full-title] Il Giornale di chirurgia
  • [ISO-abbreviation] G Chir
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


12. Colovic N, Jurisic V, Terzic T, Atkinson HD, Colovic M: Immunochemotherapy for Bcl-2 and MUM-negative aggressive primary cutaneous B-cell non-Hodgkin's lymphoma. Arch Dermatol Res; 2009 Oct;301(9):689-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunochemotherapy for Bcl-2 and MUM-negative aggressive primary cutaneous B-cell non-Hodgkin's lymphoma.
  • The case of a 44-year-old man with a primary cutaneous large B-cell non-Hodgkin's lymphoma of the scalp is reported.
  • His mother died of gastric lymphoma and his sib brother is in a 20-year remission of T-cell lymphoma.
  • The histopathology and immunohistochemistry performed in April 2006 indicated a bcl-6+, MUM- and bcl-2-, primary cutaneous follicle center B-cell non-Hodgkin's lymphoma, with an aggressive transformation to a diffuse large B-cell lymphoma.
  • Bone marrow biopsy and CT chest, abdomen, and pelvis were negative for systemic lymphoma.
  • The protracted indolent phase of the disease, the familial history of lymphoma, the histological aggressive features and the patient's excellent response to immunochemotherapy all contribute to a very unusual manifestation of this disease.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large B-Cell, Diffuse / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19495780.001).
  • [ISSN] 1432-069X
  • [Journal-full-title] Archives of dermatological research
  • [ISO-abbreviation] Arch. Dermatol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, Neoplasm; 0 / Antineoplastic Agents; 0 / BCL2L15 protein, human; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / TRAPPC1 protein, human; 0 / Vesicular Transport Proteins; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


13. Fink-Puches R, Wolf IH, Zalaudek I, Kerl H, Cerroni L: Treatment of primary cutaneous B-cell lymphoma with rituximab. J Am Acad Dermatol; 2005 May;52(5):847-53
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of primary cutaneous B-cell lymphoma with rituximab.
  • Intravenous administration of rituximab has been used for the treatment of patients with low-, intermediate-, and high-grade B-cell non-Hodgkin's lymphomas and is a registered treatment modality for this indication.
  • Treatment of primary cutaneous B-cell lymphoma (CBCL) with intralesionally or systemically administered rituximab has been described only in a few cases.
  • OBJECTIVE: Our purpose was to assess the efficacy of rituximab in the treatment of CBCL.
  • METHODS: We performed a retrospective study on 9 patients with CBCL who were treated with intralesional or systemic administration of rituximab.
  • CONCLUSION: Rituximab therapy is a well-tolerated and effective treatment for primary CBCL.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, B-Cell / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15858476.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


14. Jardin F, Lévesque H, Tilly H: [Auto-immune manifestations in Non-Hodgkin's lymphoma]. Rev Med Interne; 2005 Jul;26(7):557-71
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Auto-immune manifestations in Non-Hodgkin's lymphoma].
  • PURPOSE: A wide spectrum of auto-immune manifestations is frequently reported in non-Hodgkin's lymphoma (NHL).
  • CURRENT KNOWLEDGE AND KEY POINTS: Most of the organs can be targeted by an immune process due to the lymphoproliferative disease: they include skin diseases (paraneoplastic pemphigus, vasculitis, urticaria, acrosyndromes), peripheral and central nervous system involvement (polyneuropathy, multifocal neuropathy), haematological manifestations (immune cytopenia, acquired bleeding disorders), rheumatologic diseases (arthritis, systemic vasculitis, myositis) and renal lesion (cryoglobulinemia, glomerulopathies).
  • In B-cell NHL, clinical and biological immune manifestations are more frequently observed in indolent lymphoma than in aggressive NHL.
  • In T-cell NHL, immune manifestations are frequent and polymorphous, preceding usually the diagnosis of lymphoma.
  • The physiopathology of the immune manifestations may involve auto-antibodies production by natural CD5+ autoreactive B-cell from which is issue the proliferation, a lost of immune tolerance, an abnormality in the Fas/Fas Ligand pathway or a chronic antigenic stimulation.
  • FUTURE PROSPECTS AND PROJECTS: As observed in T-cell lymphoma cases, immunosuppressive treatment can control both immune manifestations and lymphoproliferation, suggesting that lymphoma and auto-immunity may be the two aspects of the same process.
  • The monoclonal antibody anti-CD20 (rituximab), able to suppress the tumoral cells and change the B-cell repertoire is the most promising treatment to cure immune disorders related to NHL.

  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15996570.001).
  • [ISSN] 0248-8663
  • [Journal-full-title] La Revue de medecine interne
  • [ISO-abbreviation] Rev Med Interne
  • [Language] FRE
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antibodies, Antinuclear; 0 / Antibodies, Antiphospholipid; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 169
  •  go-up   go-down


15. Duparc A, Canonne-Courivaud D, Rose C, Creusy C, Modiano P: [A pseudotumoral cutaneous form of sarcoidosis associated with non-Hodgkin lymphoma]. Ann Dermatol Venereol; 2009 Jun-Jul;136(6-7):518-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A pseudotumoral cutaneous form of sarcoidosis associated with non-Hodgkin lymphoma].
  • [Transliterated title] Sarcoïdose cutanée pseudotumorale associée à un lymphome malin non hodgkinien.
  • BACKGROUND: Sarcoidosis may be revealed by a variety of cutaneous signs, occasionally atypical.
  • It may also be associated with a lymphoma.
  • Herein we report an original case of pseudotumoral cutaneous sarcoidosis associated with malignant non-Hodgkin's lymphoma (MNHL).
  • PATIENTS AND METHODS: A 64-year-old man was hospitalised for follicular and diffuse large B-cell MNHL localised in the cervical, subclavicular and inguinal lymph nodes.
  • The skin examination revealed a bulky, erythematous, purple, infiltrated mass in the right lumbar region and two similar but smaller plaques in the dorsal region.
  • Histological examination of a skin biopsy sample revealed an epithelioid giant-cell granuloma without caseous necrosis.
  • A diagnosis of cutaneous and pulmonary sarcoidosis associated with the lymphoma was made.
  • Polychemotherapy using CHOP combined with rituximab resulted in remission of the lymphoma but was ineffective against the sarcoidosis.
  • In our case, the cutaneous mass was evocative of a secondary lymphoma site.
  • The appearance of a lymphoma in a patient with a history of sarcoidosis is rare but not fortuitous, since the notion of "sarcoidosis-lymphoma syndrome" exists.
  • The most common forms involve Hodgkin's disease.
  • [MeSH-major] Lymphoma, Non-Hodgkin / complications. Sarcoidosis / diagnosis. Skin Diseases / diagnosis


16. Rózańska-Kudelska M, Maksimowicz T, Sieśkiewicz A: [B-cell lymphoma of the nose cavity--case report]. Otolaryngol Pol; 2008;62(4):496-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [B-cell lymphoma of the nose cavity--case report].
  • INTRODUCTION: Non-Hodgkin's lymphoma of the nose and sinuses accounts for 5,8-8% of the tumors in that localisation.
  • Large B-cell lymphoma (DLBCL) are frequent in mediastinum, nasopharynx, stomach and retroperitoneal space.
  • AIM: The aim of the study was to show a case of the female patient presented DLBCL-lymphoma of the right nose cavity and cutaneous lymphoma of the right lower leg.
  • MATERIAL AND METHODS: We described a case of the 68-year-old female diagnosed in Otolaryngology Clinic of the Medical University in Bialystok with DLBCL-lymphoma of the right nose cavity.
  • One month later two tumors on the skin of the right lower leg was appeared (histological: DLBCL-lymphoma).
  • CONCLUSIONS: We present the case of the rare occurrence of a DLBCL-lymphoma of the nose cavity and the skin of the lower leg.
  • Chemotherapy, immunochemotherapy and radiotherapy are suitable treatment fort that type of lymphoma.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / therapy. Paranasal Sinus Neoplasms / pathology. Paranasal Sinus Neoplasms / therapy. Skin Neoplasms / pathology. Skin Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18837234.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


17. Charavin-Cocuzza M, Templier I, Simon A, Salameire D, Cuchet E, Reymond JL, Beani JC, Leccia MT: [Febrile cellulitis surrounding a scar revealing a large immunoblastic B-cell lymphoma]. Ann Dermatol Venereol; 2008 Dec;135(12):848-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Febrile cellulitis surrounding a scar revealing a large immunoblastic B-cell lymphoma].
  • BACKGROUND: Secondary skin sites of lymphoma appear in the advanced stages of the disease.
  • We report the first case of a pericicatricial skin infiltration, mimicking febrile dermohypodermitis, revealing diffuse immunoblastic large B-cell non-Hodgkin's lymphoma.
  • Blood cultures and bacteriological analysis of skin biopsy samples were negative.
  • Histological analysis and immunolabelling pointed to immunoblastic large B-cell non-Hodgkin's lymphoma.
  • A clone of B lymphocytes CD45+, CD20+, CD79a+, Bcl2+, CD5+, MUM1+, CD3-, CD10-, CD23- and Bcl6- was seen.
  • DISCUSSION: Secondary skin manifestations of lymphoma are generally non-specific (pruritus, ichthyosis, purpura, etc.) rather than specific in terms of lymphoid infiltration.
  • As in our patient, certain cutaneous sites of lymphoma may have a misleading clinical presentation, histological analysis alone was able to provide a conclusive diagnosis.
  • In our patient, the highly specific infiltration seen around the entire scar could either suggest a Koebner phenomenon or point to a role of the cutaneous aggression within the development of an inflammatory process contributing to pericicatricial infiltration by lymphoid cells.
  • [MeSH-major] Cellulitis / diagnosis. Head and Neck Neoplasms. Lymphoma, B-Cell. Lymphoma, Large-Cell, Immunoblastic. Skin Neoplasms
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Cicatrix / pathology. Cyclophosphamide / therapeutic use. Diagnosis, Differential. Doxorubicin / therapeutic use. Humans. Immunohistochemistry. Male. Middle Aged. Prednisone / therapeutic use. Rituximab. Skin / pathology. Treatment Outcome. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Cellulitis.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19084696.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


18. Girtovitis F, Papadopoulos A, Ntaios G, Kaloutsi V, Kotoula V, Kaiafa G: Coexistence of B-cell non-Hodgkin lymphoma and cutaneous T-cell lymphoma in a patient with chronic hepatitis C and cryoglobulinaemia. Intern Med J; 2009 Aug;39(8):550-3
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coexistence of B-cell non-Hodgkin lymphoma and cutaneous T-cell lymphoma in a patient with chronic hepatitis C and cryoglobulinaemia.
  • The coexistence of chronic active hepatitis C with cryoglobulinemia and B-cell lymphoma has been presented in numerous case reports.
  • However, the combination of these conditions with T-cell lymphoma has never been described before.
  • We present the case of a patient who suffered chronic active hepatitis C, cryoglobulinaemia and B-cell lymphoma and was later complicated by cutaneous T-cell lymphoma (CTCL).
  • [MeSH-major] Cryoglobulinemia / complications. Hepatitis C, Chronic / complications. Lymphoma, B-Cell / complications. Lymphoma, T-Cell, Cutaneous / complications
  • [MeSH-minor] Adult. Bone Marrow Neoplasms / complications. Bone Marrow Neoplasms / virology. Female. Humans. Kidney Neoplasms / complications. Kidney Neoplasms / diagnosis. Kidney Neoplasms / virology. Liver Neoplasms / complications. Liver Neoplasms / virology. Skin Neoplasms / complications. Skin Neoplasms / virology


19. Gruson LM, Latkowski JA: Diffuse large cell non-Hodgkin's lymphoma, CD30+, T-cell phenotype. Dermatol Online J; 2005;11(4):17
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse large cell non-Hodgkin's lymphoma, CD30+, T-cell phenotype.
  • A diagnosis of CD30+ cutaneous T-cell lymphoma was made, and the patient is currently undergoing staging of his disease.
  • [MeSH-major] Antigens, CD30 / analysis. Lymphoma, T-Cell, Cutaneous / pathology. Skin Neoplasms / pathology. T-Lymphocytes / immunology

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16403389.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD30
  •  go-up   go-down


20. Le EN, Gerstenblith MR, Gelber AC, Manno RL, Ranasinghe PD, Sweren RJ, McGirt LY: The use of blind skin biopsy in the diagnosis of intravascular B-cell lymphoma. J Am Acad Dermatol; 2008 Jul;59(1):148-51
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of blind skin biopsy in the diagnosis of intravascular B-cell lymphoma.
  • Intravascular B-cell lymphoma is a rare type of non-Hodgkin's lymphoma that is characterized by a clonal proliferation of lymphoblasts within small blood vessels.
  • We report a case of intravascular B-cell lymphoma, characterized by pyrexia, anemia, thrombocytopenia, and mental status decline, without obvious cutaneous manifestations, that was diagnosed with blind skin biopsy.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Skin / pathology. Vascular Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18406005.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Maksimovic O, Bethge WA, Pintoffl JP, Vogel M, Claussen CD, Bares R, Horger M: Marginal zone B-cell non-Hodgkin's lymphoma of mucosa-associated lymphoid tissue type: imaging findings. AJR Am J Roentgenol; 2008 Sep;191(3):921-30
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Marginal zone B-cell non-Hodgkin's lymphoma of mucosa-associated lymphoid tissue type: imaging findings.
  • OBJECTIVE: The aim of this essay is to describe the imaging features of marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT) type throughout various organs.
  • CONCLUSION: Awareness of the expected locations of MALT lymphoma combined with knowledge of the incidence and imaging findings leads to accurate diagnosis of lesions suspicious for this disorder and helps to differentiate this disease from other abnormalities.
  • [MeSH-major] Biliary Tract Neoplasms / diagnosis. Breast Neoplasms / diagnosis. Gastrointestinal Neoplasms / diagnosis. Lung Neoplasms / diagnosis. Lymphoma, B-Cell, Marginal Zone / diagnosis. Magnetic Resonance Imaging / methods. Skin Neoplasms / diagnosis. Tomography, X-Ray Computed / methods


22. Scheinpflug K, Schalk E, Mohren M: Staphylococcal scalded skin syndrome in an adult patient with T-lymphoblastic non-Hodgkin's lymphoma. Onkologie; 2008 Nov;31(11):616-9
Genetic Alliance. consumer health - Lymphoblastic lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Staphylococcal scalded skin syndrome in an adult patient with T-lymphoblastic non-Hodgkin's lymphoma.
  • BACKGROUND: Staphylococcal scalded skin syndrome (SSSS) is an exfoliative dermatitis caused by Staphylococcus aureus infection.
  • PATIENT AND METHODS: We report a case of SSSS in a young female patient with T-lymphoblastic lymphoma, who survived this potentially lethal complication.
  • CONCLUSIONS: To the best of our knowledge, this is the first case of SSSS in an adult patient with T-lymphoblastic non-Hodgkin's lymphoma.
  • [MeSH-major] Lymphoma, T-Cell, Cutaneous / complications. Lymphoma, T-Cell, Cutaneous / diagnosis. Staphylococcal Scalded Skin Syndrome / diagnosis. Staphylococcal Scalded Skin Syndrome / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19145095.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 43B2M34G2V / Floxacillin
  •  go-up   go-down


23. Oumeish OY, Oumeish I, Tarawneh M, Salman T, Sharaiha A: Necrobiotic xanthogranuloma associated with paraproteinemia and non-Hodgkin's lymphoma developing into chronic lymphocytic leukemia: the first case reported in the literature and review of the literature. Int J Dermatol; 2006 Mar;45(3):306-10
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Necrobiotic xanthogranuloma associated with paraproteinemia and non-Hodgkin's lymphoma developing into chronic lymphocytic leukemia: the first case reported in the literature and review of the literature.
  • The cutaneous lesions were xanthomatous nodules and plaques, affecting the periorbital regions.
  • The skin lesions became painful, pruritic, ulcerated tumors (Fig. 3).
  • These findings were suggestive of lymphoma.
  • It was concluded from the lymph node biopsies that these changes were typical of non-Hodgkin's lymphoma, diffuse and small cell type, of low-grade malignancy.
  • The bone marrow picture was consistent with diffuse, well-differentiated non-Hodgkin's lymphoma, developing into chronic lymphocytic leukemia (CLL).
  • Skin biopsy from a fresh lesion on the back showed a diffuse inflammatory cell infiltrate with collections of histiocytic cells.
  • The patient was treated by the oncologist for her lymphoma, and was given Cytoxan, prednisolone, endoxan, Leukeran, and melphalan.
  • The treatment of her skin lesions was unsatisfactory in spite of the fact that she was given cyclosporine and both systemic and topical corticosteroids.
  • [MeSH-major] Granuloma / pathology. Leukemia, Lymphocytic, Chronic, B-Cell / etiology. Lymphoma, Non-Hodgkin / complications. Necrobiotic Disorders / pathology. Paraproteinemias / etiology. Xanthomatosis / pathology
  • [MeSH-minor] Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Chlorambucil / administration & dosage. Cyclophosphamide / administration & dosage. Female. Glucocorticoids / therapeutic use. Humans. Melphalan / administration & dosage. Middle Aged. Skin Diseases / etiology. Skin Diseases / pathology. Treatment Failure. Treatment Outcome

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Xanthogranuloma.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. CHLORAMBUCIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16533236.001).
  • [ISSN] 0011-9059
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Glucocorticoids; 18D0SL7309 / Chlorambucil; 8N3DW7272P / Cyclophosphamide; Q41OR9510P / Melphalan
  •  go-up   go-down


24. Motegi S, Okada E, Nagai Y, Tamura A, Ishikawa O: Skin manifestation of mantle cell lymphoma. Eur J Dermatol; 2006 Jul-Aug;16(4):435-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skin manifestation of mantle cell lymphoma.
  • Mantle cell lymphoma (MCL) is a distinct type of non-Hodgkin's lymphoma that commonly affects extranodal sites.
  • The most commonly affected sites are bone marrow, gastrointestinal tract and Waldeyer's ring, however, skin is rarely involved.
  • We reported a 62-year-old Japanese patient with MCL, exhibiting multiple small dome-shaped red nodules and skin ulcers.
  • Our patient showed a significant improvement of skin lesions and lymphadenopathy with a combination chemotherapy.
  • Awareness of skin manifestations of MCL is essential for dermatologists to establish an early diagnosis and perform appropriate treatment.
  • [MeSH-major] Lymphoma, Mantle-Cell / pathology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16935806.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 21
  •  go-up   go-down


25. Rech J, Repp R, Rech D, Stockmeyer B, Dechant M, Niedobitek G, Gramatzki M, Valerius T: A humanized HLA-DR antibody (hu1D10, apolizumab) in combination with granulocyte colony-stimulating factor (filgrastim) for the treatment of non-Hodgkin's lymphoma: a pilot study. Leuk Lymphoma; 2006 Oct;47(10):2147-54
Hazardous Substances Data Bank. Filgrastim .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A humanized HLA-DR antibody (hu1D10, apolizumab) in combination with granulocyte colony-stimulating factor (filgrastim) for the treatment of non-Hodgkin's lymphoma: a pilot study.
  • Apolizumab is a humanized monoclonal antibody against a polymorphic epitope on HLA DRbeta that demonstrated evidence for therapeutic activity in follicular lymphoma patients.
  • In pre-clinical studies, we previously reported that granulocyte colony-stimulating factor (G-CSF) treatment significantly enhanced lymphoma cell killing by HLA class II antibodies, including apolizumab.
  • In this trial, we treated six patients with relapsed or refractory 1D10-positive non-Hodgkin's lymphoma with filgrastim and variable doses of apolizumab ranging from 0.15 to 1.5 mg/m2.
  • Another patient developed a pruritic skin rash, which was probably a treatment-related grade II skin toxicity.
  • Interestingly, two patients with follicular lymphoma who received intensified apolizumab treatment on a three times weekly schedule experienced prolonged stabilization of their disease for 12 and more than 36 months.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Granulocyte Colony-Stimulating Factor / administration & dosage. HLA-DR Antigens / immunology. Lymphoma, Non-Hodgkin / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17071489.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / HLA-DR Antigens; 0 / Recombinant Proteins; 0 / apolizumab; 143011-72-7 / Granulocyte Colony-Stimulating Factor; PVI5M0M1GW / Filgrastim
  •  go-up   go-down


26. Pothiawala SZ, Baldwin BT, Cherpelis BS, Lien MH, Fenske NA: The role of phototherapy in cutaneous T-cell lymphoma. J Drugs Dermatol; 2010 Jul;9(7):764-72
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of phototherapy in cutaneous T-cell lymphoma.
  • Cutaneous T-cell lymphoma (CTCL) is a type of non-Hodgkin's lymphoma characterized by the malignant proliferation of T lymphocytes in the skin.
  • Specifically, broadband ultraviolet B (BB-UVB), psoralen and ultraviolet A (PUVA), and more recently narrowband UVB (NB-UVB) are the skin-directed phototherapies typically utilized.
  • [MeSH-major] Lymphoma, T-Cell, Cutaneous / therapy. Phototherapy / methods. Skin Neoplasms / therapy

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20677530.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 96
  •  go-up   go-down


27. Barzilai A, Trau H, David M, Feinmesser M, Bergman R, Shpiro D, Schiby G, Rosenblatt K, Or R, Hodak E: Mycosis fungoides associated with B-cell malignancies. Br J Dermatol; 2006 Aug;155(2):379-86
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mycosis fungoides associated with B-cell malignancies.
  • BACKGROUND: The coexistence of mycosis fungoides, a peripheral T-cell lymphoma, and B-cell malignancies or Hodgkin's lymphoma in the same patient is unusual.
  • OBJECTIVES: To detect cases of mycosis fungoides associated with B-cell malignancies or Hodgkin's lymphoma and to analyse the characteristics of and the interplay between the lymphoproliferative neoplasms.
  • METHODS: Patients with mycosis fungoides who had B-cell malignancies or Hodgkin's lymphoma were selected from among 398 patients either treated or followed up in two tertiary medical centres during a 7-year period.
  • RESULTS: Eleven patients with mycosis fungoides and B-cell malignancy were detected (seven of non-Hodgkin's lymphoma, three of chronic lymphocytic leukaemia, one of multiple myeloma).
  • No case of Hodgkin's lymphoma was found.
  • In seven patients the mycosis fungoides preceded the B-cell malignancy whereas in four it was the B-cell malignancy which occurred first.
  • Among the four patients in whom the appearance of mycosis fungoides followed the B-cell malignancy, three had been treated with multiagent chemotherapy.
  • Two patients who presented with early-stage mycosis fungoides (IA) as the first lymphoma developed mycosis fungoides tumours after becoming immunosuppressed.
  • In two patients infiltrates composed of both malignant T- and B-cell populations were found in a single biopsy.
  • One showed two distinct populations of the malignant cells in the skin tumour, thus constituting a classical composite lymphoma of mycosis fungoides and chronic lymphocytic leukaemia, while in the other patient the two malignant populations of marginal B-cell lymphoma and mycosis fungoides (as evidenced by both phenotypic and genotypic findings) were intermingled.
  • CONCLUSIONS: This case series indicates that while the coexistence of Hodgkin's lymphoma and mycosis fungoides is extremely rare, the association of mycosis fungoides and B-cell malignancies is not as rare as reflected in the literature, with non-Hodgkin's lymphoma constituting the most common associated B-cell malignancy.
  • In this series as well as in the cases reported in the literature mycosis fungoides usually preceded the development of B-cell malignancies, which may be in accordance with previous reports of an increased risk of developing a second haematological neoplasm.
  • It is suggested that for greater precision the criteria for diagnosis of composite lymphoma of the skin should include both phenotypic and genotypic features.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Mycosis Fungoides / pathology. Neoplasms, Multiple Primary / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Hodgkin Disease / pathology. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Lymphoma, T-Cell, Peripheral / pathology. Male. Middle Aged

  • Genetic Alliance. consumer health - Mycosis fungoides.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16882178.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


28. Mendeszoon MJ, Wire KR: Diffuse large B-cell lymphoma of the ankle: a case study of surgical intervention and outcome. J Am Podiatr Med Assoc; 2010 Nov-Dec;100(6):505-10
Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse large B-cell lymphoma of the ankle: a case study of surgical intervention and outcome.
  • The most common type of non-Hodgkin's lymphoma is the B-cell type.
  • We report herein a type of B-cell lymphoma in an adult ankle.
  • A 63-year-old woman presented with a painful growth on the anteromedial aspect of her right ankle that was later diagnosed as a form of non-Hodgkin's lymphoma.
  • The overlying skin was friable, and the lesion did not transilluminate.
  • Histopathologic examination revealed a diffuse large B-cell lymphoma of germinal center origin on surgical excision.
  • This case report focuses on the clinical presentation, surgical intervention, and overall outcome of a rare case of lymphoma of the ankle.
  • [MeSH-major] Ankle. Lymphoma, Large B-Cell, Diffuse / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21084539.001).
  • [ISSN] 1930-8264
  • [Journal-full-title] Journal of the American Podiatric Medical Association
  • [ISO-abbreviation] J Am Podiatr Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Arcaini L, Burcheri S, Rossi A, Paulli M, Bruno R, Passamonti F, Brusamolino E, Molteni A, Pulsoni A, Cox MC, Orsucci L, Fabbri A, Frezzato M, Voso MT, Zaja F, Montanari F, Merli M, Pascutto C, Morra E, Cortelazzo S, Lazzarino M: Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT. Ann Oncol; 2007 Feb;18(2):346-50
MedlinePlus Health Information. consumer health - Hepatitis C.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT.
  • BACKGROUND: Hepatitis C virus (HCV) infection is frequently associated with B-cell non-Hodgkin's lymphomas.
  • METHODS: We retrospectively studied 172 patients with a histological diagnosis of marginal zone B-cell lymphoma of MALT, except for stomach, and with available HCV serology, among a series of 208 patients.
  • HCV-positive patients showed a more frequent involvement of skin (35%), salivary glands (25%), and orbit (15%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17071937.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / Biomarkers
  •  go-up   go-down


30. Funk A, Hensley F, Krempien R, Neuhof D, Van Kampen M, Treiber M, Roeder F, Timke C, Herfarth K, Helmbold P, Debus J, Bischof M: Palliative total skin electron beam therapy (TSEBT) for advanced cutaneous T-cell lymphoma. Eur J Dermatol; 2008 May-Jun;18(3):308-12
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Palliative total skin electron beam therapy (TSEBT) for advanced cutaneous T-cell lymphoma.
  • Our aim was to analyze the effectiveness of palliative total skin electron beam therapy (TSEBT) in the management of advanced cutaneous T-cell non-Hodgkin's lymphoma (CTCL).
  • All patients suffered from lymphoma-associated symptoms.
  • Lymphoma associated symptoms were improved in 16 patients (89%).
  • Transient grade 3 epitheliolyses developed in five patients (28%), late skin effects (grade 1 and 2) in 16 patients (89%), and hypohidrosis was seen in six patients (33%).
  • [MeSH-major] Lymphoma, T-Cell, Cutaneous / radiotherapy. Mycosis Fungoides / radiotherapy. Palliative Care / methods. Radiotherapy, High-Energy. Skin Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Electrons / adverse effects. Electrons / therapeutic use. Female. Humans. Kaplan-Meier Estimate. Lymphoma, Large-Cell, Anaplastic / pathology. Lymphoma, Large-Cell, Anaplastic / radiotherapy. Male. Middle Aged. Neoplasm Staging. Radiotherapy Dosage. Remission Induction. Retrospective Studies. Sezary Syndrome / pathology. Sezary Syndrome / radiotherapy. Survival Rate. Treatment Outcome. Whole-Body Irradiation / adverse effects. Whole-Body Irradiation / methods

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18474461.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  •  go-up   go-down


31. Scholl S, Hocke M, Hoffken K, Sayer HG: Acute abdomen by varicella zoster virus induced gastritis after autologous peripheral blood stem cell transplantation in a patient with non-Hodgkin's lymphoma. Acta Haematol; 2006;116(1):58-61
Hazardous Substances Data Bank. ACYCLOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute abdomen by varicella zoster virus induced gastritis after autologous peripheral blood stem cell transplantation in a patient with non-Hodgkin's lymphoma.
  • We report on a 54-year-old male patient with an aggressive T cell non-Hodgkin's lymphoma with abdominal manifestation undergoing autologous peripheral blood stem cell transplantation after high-dose chemotherapy in April 2003.
  • No herpetic skin lesions were observed at any time during the disease.
  • This report demonstrates the importance of viral-induced gastritis in the differential diagnosis of severe abdominal pain in patients receiving autologous peripheral blood stem cell transplantation.
  • [MeSH-major] Abdomen, Acute / drug therapy. Acyclovir / administration & dosage. Antiviral Agents / administration & dosage. Gastritis / drug therapy. Herpes Zoster / drug therapy. Herpesvirus 3, Human. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Diagnosis, Differential. Gastroscopy. Humans. Male. Middle Aged. Peripheral Blood Stem Cell Transplantation. Pyloric Antrum / virology. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Shingles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16809891.001).
  • [ISSN] 0001-5792
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antiviral Agents; X4HES1O11F / Acyclovir
  •  go-up   go-down


32. Brown JR, Yeckes H, Friedberg JW, Neuberg D, Kim H, Nadler LM, Freedman AS: Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol; 2005 Apr 1;23(10):2208-14
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma.
  • We report the incidence and outcome of solid tumors at 10-year follow-up in a large cohort of uniformly treated patients who underwent ABMT for non-Hodgkin's lymphoma (NHL).
  • PATIENTS AND METHODS: Between 1982 and 1997, 605 patients underwent ABMT for B-cell NHL, with uniform conditioning with cyclophosphamide and total-body irradiation followed by reinfusion of autologous bone marrow purged with anti-B-cell monoclonal antibodies.
  • RESULTS: Forty-two solid tumors, six non-MDS hematologic malignancies, 39 nonmelanoma skin cancers, and 68 cases of MDS/acute myelogenous leukemia (AML) were observed at a median follow-up of 9.5 years.
  • A cumulative incidence model using death as a competing risk found that the 10-year incidence of second malignancy is 21%, with 10.0% non-MDS malignancies.
  • [MeSH-major] Antineoplastic Agents, Alkylating / adverse effects. Antineoplastic Agents, Alkylating / therapeutic use. Bone Marrow Transplantation. Cyclophosphamide / adverse effects. Cyclophosphamide / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy. Neoplasms / epidemiology. Neoplasms / etiology. Neoplasms, Second Primary / epidemiology. Neoplasms, Second Primary / etiology. Whole-Body Irradiation / adverse effects

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2005 Nov 1;23(31):8120-1; author reply 8121-2 [16258113.001]
  • (PMID = 15753460.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


33. Rawal YB, Nuovo GJ, Frambach GE, Porcu P, Baiocchi RA, Magro CM: The absence of CD20 messenger RNA in recurrent cutaneous B-cell lymphoma following rituximab therapy. J Cutan Pathol; 2005 Oct;32(9):616-21
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The absence of CD20 messenger RNA in recurrent cutaneous B-cell lymphoma following rituximab therapy.
  • BACKGROUND: Rituximab has been used to treat relapsed low-grade or advanced non-Hodgkin's lymphoma since 1997, targeting the CD20 antigen expressed by B cells.
  • METHODS: Four patients with CD20-positive cutaneous B-cell lymphoma received rituximab therapy with subsequent recurrences.
  • RESULTS: Cutaneous relapses occurring within 1.5-3 months following the last dose of rituximab were CD20 negative.
  • CONCLUSIONS: Rituximab may be associated with the emergence of CD20-negative B-cell clones, potentially rendering a tumor insensitive to this drug.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antigens, CD20 / metabolism. Antineoplastic Agents / therapeutic use. Lymphoma, B-Cell / drug therapy. Neoplasm Recurrence, Local / metabolism. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16176299.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


34. Niiyama S, Satoh K, Kaneko S, Aiba S, Takahashi M, Mukai H: Zosteriform skin involvement of nodal T-cell lymphoma: a review of the published work of cutaneous malignancies mimicking herpes zoster. J Dermatol; 2007 Jan;34(1):68-73
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Zosteriform skin involvement of nodal T-cell lymphoma: a review of the published work of cutaneous malignancies mimicking herpes zoster.
  • A 77-year-old Japanese woman initially presented with non-Hodgkin's lymphoma involving her neck, axillary and inguen lymph nodes.
  • She had edematous erythema and nodules limited to the skin in zosteriform distribution on the left side chest wall along the T4-5 dermatome.
  • In addition, since 1970, we have mainly been collecting English-language articles on malignant skin tumors and skin metastasis described as zosteriform in the title, and we have reviewed a total of 29 cases, including our own.
  • We wish to add the dermatomic eruption mimicking zoster sine herpete to the list of possible presentations of cutaneous malignancies.
  • [MeSH-major] Lymphoma, T-Cell, Cutaneous / pathology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17204106.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 39
  •  go-up   go-down


35. Huber MA, Staib G, Pehamberger H, Scharffetter-Kochanek K: Management of refractory early-stage cutaneous T-cell lymphoma. Am J Clin Dermatol; 2006;7(3):155-69
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of refractory early-stage cutaneous T-cell lymphoma.
  • Cutaneous T-cell lymphoma (CTCL) is a heterogeneous group of non-Hodgkin's lymphomas that manifest primarily in the skin.
  • However, although there is a wide array of therapeutic options for early-stage CTCL, not all patients respond to these individual therapies, resulting in refractory cutaneous disease over time.
  • Refractory early-stage CTCL poses an important therapeutic challenge, as one of the principal treatment goals is to keep the disease confined to the skin, thereby preventing disease progression.
  • Much of the focus of current research has been on the evaluation of already available skin-directed therapies and biologic response modifiers and combination regimens thereof, such as the combination of psoralen and UVA (PUVA) with interferon-alpha or retinoids.
  • Systemic chemotherapy is typically reserved for advanced-stage CTCL and is usually not recommended for early-stage, skin-limited disease.
  • [MeSH-major] Lymphoma, T-Cell, Cutaneous / therapy. Skin Neoplasms / therapy

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16734503.001).
  • [ISSN] 1175-0561
  • [Journal-full-title] American journal of clinical dermatology
  • [ISO-abbreviation] Am J Clin Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Antineoplastic Agents; 0 / Immunologic Factors; 0 / Retinoids
  • [Number-of-references] 93
  •  go-up   go-down


36. Vitolo U, Ferreri AJ, Zucca E: Primary testicular lymphoma. Crit Rev Oncol Hematol; 2008 Feb;65(2):183-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary testicular lymphoma.
  • Primary non-Hodgkin's lymphoma of the testis (PTL) accounts for about 9% of testicular neoplasms and 1-2% of all non-Hodgkin's lymphomas.
  • Diffuse large B-cell lymphoma (DLBCL) is the most common histotype in primary forms; aggressive histologies, especially Burkitt's lymphoma, are prevalent in cases of secondary involvement of testis.
  • PTL has a propensity to disseminate to other extranodal organs, including the controlateral testis, CNS, skin, Waldeyer's ring, lung, pleura, and soft tissue.
  • [MeSH-major] Lymphoma, Non-Hodgkin. Testicular Neoplasms

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17962036.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 40
  •  go-up   go-down


37. Li BZ, Zhou XY, Ye HT, Yang WT, Fan YZ, Lu HF, Shi DR: [Abnormal expression of bcl-10 protein in extranodal marginal zone B cell lymphoma of mucosa-associated lymphoid tissue lymphoma type]. Zhonghua Bing Li Xue Za Zhi; 2007 Dec;36(12):819-24

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Abnormal expression of bcl-10 protein in extranodal marginal zone B cell lymphoma of mucosa-associated lymphoid tissue lymphoma type].
  • OBJECTIVE: To evaluate the diagnostic role of nuclear expression of bcl-10 protein in extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) type.
  • METHODS: One hundred and forty cases of MALT lymphoma were collected from Cancer Hospital of Fudan University (including 38 cases from stomach, 35 cases from ocular adnexa, 16 cases from intestine, 15 cases from skin, 15 cases from salivary gland, 14 cases from lung, 3 cases from thyroid and 4 cases from other sites).
  • Ten cases of reactive follicular hyperplasia of tonsil, 5 cases of reactive lymphoid hyperplasia of orbit and 143 cases of non-Hodgkin's lymphoma other than MALT lymphoma (including 20 cases of NK/T cell lymphoma, 20 cases of follicular lymphomas, 20 cases of anaplastic large cell lymphomas, 20 cases of nodal diffuse large cell B-cell lymphoma (DLBCL), 10 cases of gastric diffuse large B-cell lymphoma, 13 cases of nodal marginal zone B-cell lymphoma, 12 cases of mantle cell lymphoma, 11 cases of splenic marginal zone B-cell lymphoma, 6 cases of angioimmunoblastic T-cell lymphoma, 6 cases of peripheral T-cell lymphoma, not otherwise specified, 3 cases of small lymphocytic lymphoma, 1 case of lymphoplasmacytic lymphoma and 1 case of plasmacytoma were used as controls.
  • As for non-MALT lymphomas, 3 gastric DLBCL showed nuclear expression.
  • In some cases of lymphoma, bcl-10 was expressed in tumor cells but not in reactive lymphoid cells.
  • On the other hand, 92.1% (129/140) of MALT lymphoma were bcl-10 positive.
  • The staining was most intense in MALT lymphoma of ocular adnexa.
  • Cytoplasmic expression of bcl-10 is seen in many different kinds of non-Hodgkin's lymphoma and reactive lymphoid conditions.
  • In some cases of lymphoma, bcl-10 is expressed in tumor cells but not in reactive lymphoid cells, suggesting a possible role of abnormal bcl-10 expression in tumorgenesis.
  • Nuclear expression of bcl-10 is seen mainly in MALT lymphoma, especially when occurring in ocular adnexa and lung.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / genetics. Gene Expression Regulation, Neoplastic. Lymphoma, B-Cell, Marginal Zone / genetics. Lymphoma, B-Cell, Marginal Zone / pathology
  • [MeSH-minor] Antigens, CD20 / immunology. Cell Nucleus / genetics. Cytoplasm / genetics. Humans. Lymphocytes / pathology. Palatine Tonsil / pathology. Pseudolymphoma / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18346354.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Antigens, CD20; 0 / BCL10 protein, human
  •  go-up   go-down


38. Leenman EE, Krivolapov IuA, Morozova EV: [T-cell panniculitis-like lymphoma of the subcutaneous fat: clinicomorphological and immunohistochemical analysis]. Arkh Patol; 2005 Mar-Apr;67(2):43-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [T-cell panniculitis-like lymphoma of the subcutaneous fat: clinicomorphological and immunohistochemical analysis].
  • 3 cases of T-cell panniculitis-like lymphoma of the subcutaneous fat are reported.
  • T-cell panniculitis-like lymphoma is a special variant of non-Hodgkin's lymphoma which is diagnosed immunohistochemically.
  • [MeSH-major] Lymphoma, T-Cell, Cutaneous / pathology. Panniculitis / diagnosis. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Panniculitis.
  • Genetic Alliance. consumer health - Subcutaneous panniculitis-like T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15938121.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antigens, CD
  •  go-up   go-down


39. Introcaso CE, Leber B, Greene K, Ubriani R, Rook AH, Kim EJ: Stem cell transplantation in advanced cutaneous T-cell lymphoma. J Am Acad Dermatol; 2008 Apr;58(4):645-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stem cell transplantation in advanced cutaneous T-cell lymphoma.
  • Cutaneous T-cell lymphomas are a type of indolent non-Hodgkin's lymphoma where patients with limited skin disease can be successfully treated with a variety of skin-directed, systemic, and immunomodulating therapies, whereas durable remissions are difficult to achieve in patients with tumor, erythrodermic, or systemic disease.
  • We describe a patient with cutaneous T-cell lymphoma and malignant cells constituting 99% of her peripheral blood lymphocytes who had a sustained complete response after an HLA-matched sibling allogeneic stem cell transplantation.
  • We also review the current literature regarding both autologous and allogeneic stem cell transplantations for advanced stages of cutaneous T-cell lymphoma, discuss the importance of the graft-versus-tumor immunomodulatory effect in successful transplantations, and suggest that allogeneic stem cell transplantation deserves further consideration and study as a potential treatment for selected patients who are younger and at high risk.
  • [MeSH-major] Lymphoma, T-Cell, Cutaneous / surgery. Mycosis Fungoides / surgery. Stem Cell Transplantation

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18258335.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 19
  •  go-up   go-down


40. Fritzsche FR, Pahl S, Petersen I, Burkhardt M, Dankof A, Dietel M, Kristiansen G: Anaplastic large-cell non-Hodgkin's lymphoma of the breast in periprosthetic localisation 32 years after treatment for primary breast cancer--a case report. Virchows Arch; 2006 Nov;449(5):561-4
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic large-cell non-Hodgkin's lymphoma of the breast in periprosthetic localisation 32 years after treatment for primary breast cancer--a case report.
  • Primary, as well as secondary, lymphomas of the breast are rare diseases and might, in some cases, be misdiagnosed as breast cancer on routine hematoxylin/eosin stainings.
  • We report a case of an anaplastic large cell lymphoma in a 72-year-old woman with a history of breast cancer treated with breast-ablative surgery and a subsequent silicon implant 32 years ago.
  • Clinically, she presented with an ulceration of the skin, which had developed within a few months.
  • The immunoprofile of the tumor showed negativity for cytokeratins and led to the diagnosis of a CD30-positive anaplastic large cell lymphoma.
  • [MeSH-major] Breast Neoplasms / pathology. Lymphoma, Large B-Cell, Diffuse / pathology

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 2003 Mar;127(3):e115-8 [12653596.001]
  • [Cites] Arch Pathol Lab Med. 1999 Dec;123(12):1208-18 [10583925.001]
  • [Cites] Leuk Lymphoma. 2005 Sep;46(9):1321-7 [16109610.001]
  • [Cites] J Am Acad Dermatol. 1995 Jun;32(6):939-42 [7751462.001]
  • [Cites] Cancer. 1972 Jun;29(6):1705-12 [4555557.001]
  • [Cites] Ann Acad Med Singapore. 1996 Nov;25(6):783-90 [9055003.001]
  • [Cites] Am J Surg Pathol. 1994 Mar;18(3):288-95 [8116797.001]
  • [Cites] S Afr Med J. 1995 Feb;85(2):85-9 [7597540.001]
  • [Cites] Ann Saudi Med. 2005 Jul-Aug;25(4):288-93 [16212120.001]
  • [Cites] Plast Reconstr Surg. 1997 Aug;100(2):554-5 [9252643.001]
  • [Cites] J Clin Ultrasound. 2005 Mar-Apr;33(3):140-2 [15756660.001]
  • [Cites] Leuk Lymphoma. 2005 Mar;46(3):451-5 [15621838.001]
  • [Cites] Haematologica. 2003 Sep;88(9):ELT30 [12969826.001]
  • [Cites] Blood. 1996 Oct 15;88(8):3124-8 [8874212.001]
  • [Cites] J Natl Cancer Inst. 1997 Sep 17;89(18):1341-9 [9308703.001]
  • [Cites] Clin Lymphoma. 2005 Jun;6(1):37-42 [15989705.001]
  • [Cites] Am J Surg Pathol. 1995 Jun;19(6):712-7 [7755157.001]
  • [Cites] Leuk Lymphoma. 2002 Jan;43(1):115-9 [11908714.001]
  • [Cites] Clin Lymphoma Myeloma. 2006 Jan;6(4):337-41 [16507213.001]
  • [Cites] Leuk Lymphoma. 2001 Sep-Oct;42(5):1157-9 [11697637.001]
  • [Cites] Cancer Causes Control. 2004 Apr;15(3):313-9 [15090726.001]
  • [Cites] Onkologie. 2003 Jun;26(3):277-80 [12845214.001]
  • [Cites] Cancer. 2002 Jan 1;94(1):6-13 [11815954.001]
  • [Cites] Breast J. 2002 Nov-Dec;8(6):382 [12390362.001]
  • [Cites] J Clin Pathol. 2004 Nov;57(11):1213-4 [15509687.001]
  • [Cites] Am J Clin Pathol. 1997 Feb;107(2):177-86 [9024066.001]
  • (PMID = 16983530.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD30
  •  go-up   go-down


41. Querfeld C, Nagelli LV, Rosen ST, Kuzel TM, Guitart J: Bexarotene in the treatment of cutaneous T-cell lymphoma. Expert Opin Pharmacother; 2006 May;7(7):907-15
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bexarotene in the treatment of cutaneous T-cell lymphoma.
  • Primary cutaneous T-cell lymphomas encompass a spectrum of non-Hodgkin's lymphomas that are characterised by clonal proliferation of skin-homing malignant T lymphocytes.
  • Mycosis fungoides and the leukaemic variant Sézary syndrome, collectively referred to as cutaneous T-cell lymphomas, are the most common entities.
  • Bexarotene is the first synthetic nuclear retinoid X receptor-selective retinoid approved by the FDA for the treatment of refractory cutaneous T-cell lymphoma in all stages, as both an oral capsule and a topical gel formulation.
  • Bexarotene was found to induce apoptosis in a variety of preclinical in vitro and in vivo models including cutaneous T-cell lymphoma cells, and has shown efficacy in two multi-centre, open-label Phase II - III clinical trials for early and advanced stages of cutaneous T-cell lymphoma in patients who have failed or were refractory to standard therapies.
  • This article reviews the biological properties, pharmacokinetics, clinical efficacy, safety and role of bexarotene in the treatment of cutaneous T-cell lymphoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Lymphoma, T-Cell, Cutaneous / drug therapy. Skin Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16634713.001).
  • [ISSN] 1744-7666
  • [Journal-full-title] Expert opinion on pharmacotherapy
  • [ISO-abbreviation] Expert Opin Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 72
  •  go-up   go-down


42. Venizelos ID, Tatsiou ZA, Mandala E: Primary cutaneous T-cell-rich B-cell lymphoma: a case report and literature review. Acta Dermatovenerol Alp Pannonica Adriat; 2008 Dec;17(4):177-81
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous T-cell-rich B-cell lymphoma: a case report and literature review.
  • T-cell-rich B-cell lymphoma (TCRBCL) is a recently recognized B-cell lymphoma variant, characterized by a minor population of neoplastic B-cells existing in a background of predominant reactive T-lymphocytes.
  • It is a rare entity, accounting for approximately 1 to 2% of all non-Hodgkin's lymphomas.
  • Primary cutaneous TCRBCL is an extremely rare lymphoma and only 16 cases have been documented thus far in the medical literature.
  • We report the case of a 46- year-old man that presented with a slowly-growing, painless skin nodule on the left temporofrontal region of the scalp.
  • A complete surgical excision of the skin lesion and systemic chemotherapy seems to have been effective because the patient is disease-free 2 years after the initial diagnosis was made.
  • This study reports a very rare case of TCRBCL presented primarily in the skin.
  • [MeSH-major] Head and Neck Neoplasms / pathology. Lymphoma, B-Cell / pathology. Scalp / pathology. Skin Neoplasms / pathology. T-Lymphocytes / pathology

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19104743.001).
  • [ISSN] 1318-4458
  • [Journal-full-title] Acta dermatovenerologica Alpina, Pannonica, et Adriatica
  • [ISO-abbreviation] Acta Dermatovenerol Alp Pannonica Adriat
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Slovenia
  • [Number-of-references] 25
  •  go-up   go-down


43. Jardin F: Development of autoimmunity in lymphoma. Expert Rev Clin Immunol; 2008 Mar;4(2):247-66
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of autoimmunity in lymphoma.
  • Conversely, development of clinical or biological signs of autoimmunity at the time of the diagnosis of lymphoma or during its course indicates that lymphoma and autoimmune manifestations may constitute two faces of the same process.
  • The aim of this review is to describe autoimmune manifestations related to non-Hodgkin's lymphoma and Hodgkin's lymphoma, their specificity according to the lymphoma subtype and their physiopathological signification.
  • Lymphoma-related autoimmune manifestations include mainly skin diseases, hematological manifestations, rheumatic diseases and renal lesions.
  • Despite the lack of studies providing a systematic prospective assessment, autoimmune manifestations are observed in all lymphoma subtypes and seem particularly prevalent in marginal-zone lymphoma and T-cell lymphoma.
  • Monoclonal antibodies (including rituximab, Campath-1H or epratuzumab) constitute the most promising approach to treat lymphoma-related immune disorders.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20477054.001).
  • [ISSN] 1744-8409
  • [Journal-full-title] Expert review of clinical immunology
  • [ISO-abbreviation] Expert Rev Clin Immunol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


44. M'kacher R, Bennaceur-Griscelli A, Girinsky T, Koscielny S, Delhommeau F, Dossou J, Violot D, Leclercq E, Courtier MH, Béron-Gaillard N, Assaf E, Ribrag V, Bourhis J, Feneux D, Bernheim A, Parmentier C, Carde P: Telomere shortening and associated chromosomal instability in peripheral blood lymphocytes of patients with Hodgkin's lymphoma prior to any treatment are predictive of second cancers. Int J Radiat Oncol Biol Phys; 2007 Jun 1;68(2):465-71
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Telomere shortening and associated chromosomal instability in peripheral blood lymphocytes of patients with Hodgkin's lymphoma prior to any treatment are predictive of second cancers.
  • PURPOSE: To investigate a potential link between telomere length, chromosomal instability, and the advent of a second cancer (SC) in patients with Hodgkin's lymphoma (HL), who are known to be at risk for SCs.
  • [MeSH-major] Chromosomal Instability / genetics. Hodgkin Disease / genetics. Lymphocytes. Neoplasms, Second Primary / etiology. Telomere / pathology
  • [MeSH-minor] Adult. Aged. Breast Neoplasms / genetics. Carcinoma, Basal Cell / genetics. Cohort Studies. DNA Repair. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prospective Studies. Radiation Tolerance. Skin Neoplasms / genetics. Survivors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17418962.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


45. Lal A, Bhurgri Y, Vaziri I, Rizvi NB, Sadaf A, Sartajuddin S, Islam M, Kumar P, Adil S, Kakepoto GN, Masood N, Khurshed M, Alidina A: Extranodal non-Hodgkin's lymphomas--a retrospective review of clinico-pathologic features and outcomes in comparison with nodal non-Hodgkin's lymphomas. Asian Pac J Cancer Prev; 2008 Jul-Sep;9(3):453-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extranodal non-Hodgkin's lymphomas--a retrospective review of clinico-pathologic features and outcomes in comparison with nodal non-Hodgkin's lymphomas.
  • OBJECTIVE: The primary objective of this study was to analyze the anatomic distribution, clinical features and outcome of Diffuse large B-cell lymphoma (DLBCL) patients according to the primary site (extranodal vs. nodal) with applicability of International Prognostic Index (IPI).
  • The distribution according to the primary site was: lymph node (N-NHL), 322 cases (58%) of which 145(44%) were stage IV, 76(23%) stage III, 60 (18%) stage II and 47 (15%) stage I.
  • The extra nodal sites (EN-NHL) 235 (42%) cases included gastro-intestinal tract (44%), upper aerodigestive tract (19%), bones (8%), spine (5%), and unusual sites less than 3% each as breast, CNS, testis, lungs and skin.
  • In the latter this varied greatly depending on the primary site and stage of disease at presentation.
  • In the univariate analysis factors associated with good prognosis were: age less than 60 years, early stage (I-II), extranodal involvement primarily gastric or bone, 0-1 extranodal site, 0-1 performance status, lack of B symptoms and normal LDH level.
  • [MeSH-major] Lymph Nodes / pathology. Lymphoma, Extranodal NK-T-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / mortality. Lymphoma, Large B-Cell, Diffuse / pathology. Neoplasm Invasiveness / pathology
  • [MeSH-minor] Adult. Analysis of Variance. Biopsy, Needle. Cohort Studies. Confidence Intervals. Disease-Free Survival. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Lymphoma, Non-Hodgkin / mortality. Lymphoma, Non-Hodgkin / pathology. Lymphoma, Non-Hodgkin / therapy. Male. Middle Aged. Odds Ratio. Pakistan. Probability. Prognosis. Proportional Hazards Models. Retrospective Studies. Risk Assessment. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19004134.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


46. Isogai R, Fukao M, Kawada A: Successful treatment for recurrence of primary cutaneous anaplastic large-cell lymphoma in elderly patient with etoposide, mitoxantrone, cyclophosphamide, vincristine, prednisolone and bleomycin (VNCOP-B) therapy. J Dermatol; 2007 Aug;34(8):556-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment for recurrence of primary cutaneous anaplastic large-cell lymphoma in elderly patient with etoposide, mitoxantrone, cyclophosphamide, vincristine, prednisolone and bleomycin (VNCOP-B) therapy.
  • Primary cutaneous anaplastic large cell lymphoma (C-ALCL) is a malignant lymphoma with a relatively good prognosis, consisting of CD30-positive, undifferentiated, large cells.
  • In conclusion, the VNCOP-B regimen might be an effective treatment for elderly patients with good performance status, CHOP-resistant patients or patients with aggressive non-Hodgkin's lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, Large-Cell, Anaplastic / drug therapy. Neoplasm Recurrence, Local / drug therapy. Skin Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17683387.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; BZ114NVM5P / Mitoxantrone; VB0R961HZT / Prednisone; CHOP protocol; VNCOP-B protocol
  •  go-up   go-down


47. Goel K, Kini H, Rau AR, Nadar S, Pai MR, Rao HT: Cytomorphology of subcutaneous panniculitic T-cell lymphoma (SPTCL)--a case report. Indian J Pathol Microbiol; 2006 Apr;49(2):246-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytomorphology of subcutaneous panniculitic T-cell lymphoma (SPTCL)--a case report.
  • T cell lymphomas account for approximately 60% of cutaneous lymphomas.
  • The annual incidence of cutaneous lymphoma is estimated to be from 0.5 to 1 per 1,00,000 persons per year.
  • We present one case of cutaneous lymphoma, an eighteen year old male who presented with multiple swellings all over the body of one month duration.
  • On examination, multiple, subcutaneous, mobile, non tender nodules were seen ranging from 0.5 cm to 5 cm in diameter.
  • FNAC revealed non-Hodgkin's lymphoma morphologically in favour of cutaneous T-cell lymphoma.
  • [MeSH-major] Lymphoma, T-Cell, Cutaneous / pathology. Panniculitis / pathology. Skin Neoplasms / pathology. Subcutaneous Tissue / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16933726.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antigens, CD
  •  go-up   go-down


48. Pullarkat VA, Medeiros LJ, Brynes RK: Body cavity-based presentation of natural killer cell lymphoma. Leuk Lymphoma; 2005 Feb;46(2):293-6
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Body cavity-based presentation of natural killer cell lymphoma.
  • We describe an unusual case of a 31-year-old Mexican woman who presented with pleural and peritoneal effusions involved by Epstein-Barr virus-positive non-Hodgkin's lymphoma of natural killer (NK)-cell lineage.
  • Thus, this case clinically mimicked body cavity-based lymphoma.
  • Extranodal NK/T-cell lymphoma of nasal type is the current designation for these neoplasms in the recently proposed World Health Organization classification of lymphoid neoplasms.
  • These tumors previously have been referred to many other names, including lethal midline granuloma, midline malignant reticulosis, polymorphic reticulosis, angiocentric immunoproliferative lesion, and angiocentric lymphoma.
  • Nasal-type NK/T-cell lymphomas typically involve the nasal region, but may involve other extranodal sites, such as skin and gastrointestinal tract.
  • The malignant cytologic features and the presence of azurophilic granules within the cell cytoplasm observed in Wright-Giemsa-stained cytocentrifuge preparations led to immunophenotypic and molecular genetic studies that were essential in establishing the correct diagnosis.
  • As demonstrated in the case reported, extranodal NK/T-cell lymphomas of nasal-type can be clinically aggressive and may be associated with paraneoplastic phenomena.
  • [MeSH-major] Killer Cells, Natural / pathology. Lymphoma, T-Cell / pathology. Nose Neoplasms / diagnosis. Pleural Effusion, Malignant / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15621817.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


49. Chandesris MO, Crétel-Durand E, Jean R, Rey J, Figarella-Branger D, Sainty D, Durand JM: [Dermatomyositis associated with hepatosplenic gamma delta T-cell lymphoma]. Rev Med Interne; 2007 Aug;28(8):552-5
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Dermatomyositis associated with hepatosplenic gamma delta T-cell lymphoma].
  • INTRODUCTION: Peripheral T cell lymphomas are a heterogeneous group of post-thymic, mature lymphoid malignancies, accounting for approximately 10-15% of all non-Hodgkin's lymphomas.
  • A rare entity within this group is represented by hepatosplenic T cell lymphoma, characterized by primary extranodal disease with infiltration of the liver and the spleen and by expression of the T cell receptor gamma delta chain.
  • Cerebrospinal fluid analysis revealed large granular lymphomatous cells with CD3+ CD4- CD8- CD7+ CD16- CD56- surface antigens, expressing the gamma delta T-cell receptor.
  • There was no evidence of skin or bone marrow infiltration by lymphoma or any other involvement.
  • This is the first report of dermatomyositis associated with a gamma delta T-cell lymphoma (GDTL).

  • Genetic Alliance. consumer health - Dermatomyositis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17559983.001).
  • [ISSN] 0248-8663
  • [Journal-full-title] La Revue de medecine interne
  • [ISO-abbreviation] Rev Med Interne
  • [Language] FRE
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Receptors, Antigen, T-Cell, gamma-delta
  •  go-up   go-down


50. Le Deley MC, Rosolen A, Williams DM, Horibe K, Wrobel G, Attarbaschi A, Zsiros J, Uyttebroeck A, Marky IM, Lamant L, Woessmann W, Pillon M, Hobson R, Mauguen A, Reiter A, Brugières L: Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma: results of the randomized ALCL99-vinblastine trial. J Clin Oncol; 2010 Sep 1;28(25):3987-93
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma: results of the randomized ALCL99-vinblastine trial.
  • PURPOSE: The impact of adding vinblastine to a 4-month chemotherapy regimen, based on the Non-Hodgkin's Lymphoma Berlin-Frankfurt-Münster 90 protocol, in childhood high-risk anaplastic large-cell lymphoma (ALCL) was assessed.
  • PATIENTS AND METHODS: Children and adolescents with high-risk ALCL, defined by mediastinal, lung, liver, spleen, or skin involvement, were eligible for the trial.
  • The primary end point was event-free survival (EFS), analyzed on the intent-to-treat population.
  • [MeSH-minor] Adolescent. Child. Disease-Free Survival. Humans. Lymphoma, Large-Cell, Anaplastic / drug therapy

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2011 Feb 1;29(4):e90-1; author reply e92-3 [21172896.001]
  • (PMID = 20679620.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine
  •  go-up   go-down


51. Zizi-Sermpetzoglou A, Petrakopoulou N, Tepelenis N, Savvaidou V, Vasilakaki T: Intravascular T-cell lymphoma of the vulva, CD30 positive: a case report. Eur J Gynaecol Oncol; 2009;30(5):586-8
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intravascular T-cell lymphoma of the vulva, CD30 positive: a case report.
  • Primary non-Hodgkin's lymphoma involving the vulva is very rare.
  • Vulvar lymphoma is an aggressive disease.
  • A local excision of the mass followed and the final diagnosis was primary intravascular vulvar lymphoma, of T-cell origin, CD30 positive.
  • They are predominantly of B cell lineage, involving most commonly the skin and rarely other systems or organs.
  • Because of the fact that the vulva is a cutaneous site the development of intravascular lymphoma in this region is possible.
  • [MeSH-major] Lymphoma, T-Cell, Cutaneous / pathology. Vascular Neoplasms / pathology. Vulvar Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19899424.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


52. Contassot E, French LE: Targeting apoptosis defects in cutaneous T-cell lymphoma. J Invest Dermatol; 2009 May;129(5):1059-61
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeting apoptosis defects in cutaneous T-cell lymphoma.
  • Cutaneous T-cell lymphomas (CTCLs) are non-Hodgkin's lymphomas characterized by the clonal proliferation of skin-invasive mature T lymphocytes.
  • Because of their low proliferative potential, the accumulation of clonal T cells is considered to be potentially due to their inability to undergo Fas-mediated apoptosis, a crucial process involved in T-cell homeostasis.
  • [MeSH-major] Apoptosis / physiology. Lymphoma, T-Cell, Cutaneous / pathology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] J Invest Dermatol. 2009 May;129(5):1165-73 [18923451.001]
  • (PMID = 19369931.001).
  • [ISSN] 1523-1747
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Publication-type] Comment; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / CASP8 and FADD-Like Apoptosis Regulating Protein; 0 / FAS protein, human; 0 / FASLG protein, human; 0 / Fas Ligand Protein; 0 / Receptors, Death Domain
  •  go-up   go-down


53. Pujol RM, Gallardo F, Servitje O, Martí RM, Bordes R, García-Muret MP, Estrach MT, Nomdedeu JF: Peripheral T-cell lymphoma with secondary epithelioid granulomatous cutaneous involvement: a clinicopathologic study of four cases. J Dermatol; 2005 Jul;32(7):541-8
MedlinePlus Health Information. consumer health - Skin Conditions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral T-cell lymphoma with secondary epithelioid granulomatous cutaneous involvement: a clinicopathologic study of four cases.
  • Epithelioid granuloma formation has rarely been observed in specific cutaneous lesions from T-cell lymphomas other than those of mycosis fungoides/Sézary syndrome (MF/SS).
  • Three patients diagnosed with nodal and/or extranodal (tonsillar) non-Hodgkin's peripheral T-cell lymphoma (PTCL) and one patient with angioimmunoblastic T-cell lymphoma (AILD), developed specific cutaneous involvement showing prominent epithelioid cell and/or granulomatous inflammation.
  • The clinicopathological features of cutaneous involvement by PTCL showing a florid epithelioid and/or granulomatous cell reaction are reviewed.
  • [MeSH-major] Epithelioid Cells / pathology. Granuloma / complications. Lymphoma, T-Cell, Peripheral / complications. Skin Diseases / complications
  • [MeSH-minor] Aged. Female. Humans. Male. Middle Aged. Skin / pathology


54. Berg JO, Vindeløv L, Schmidt G, Drzewiecki KT: Allogeneic split-skin grafting in stem cell transplanted patients. J Plast Reconstr Aesthet Surg; 2008 Dec;61(12):1512-5
MedlinePlus Health Information. consumer health - Dandruff, Cradle Cap, and Other Scalp Conditions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic split-skin grafting in stem cell transplanted patients.
  • SUMMARY: We present a unique case of a bone marrow stem cell transplanted (BMT) patient with cutaneous chronic Graft versus Host Disease (cGvHD) who underwent successful allogeneic split-thickness skin graft (STSG) transplantation.
  • BMT had previously been carried out due to myelodysplasia and non-Hodgkin's lymphoma of the patient.
  • Allogeneic skin grafts are known to be acutely rejected.
  • This case is the first to demonstrate what works in theory: the immune system of a stem cell transplanted patient with 100% or mixed stable donor chimaerism will not recognise skin from the stem cell donor as foreign.
  • Due to advances in haematology, the number of BMT patients and their long-term survival is expected to increase. cGvHD, predisposing to skin problems and ulcerations, complicates up to 70% of cases of BMT.
  • In BMT patients with cGvHD and large skin defects, allogeneic STSC from the BMT donor seems to be a safe alternative for permanent coverage.
  • [MeSH-major] Graft vs Host Disease / surgery. Hematopoietic Stem Cell Transplantation / adverse effects. Scalp Dermatoses / surgery. Skin Transplantation / methods
  • [MeSH-minor] Chronic Disease. Female. Follow-Up Studies. Graft Survival. Histocompatibility Testing. Humans. Lymphoma, Follicular / therapy. Middle Aged. Skin Ulcer / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18158277.001).
  • [ISSN] 1878-0539
  • [Journal-full-title] Journal of plastic, reconstructive & aesthetic surgery : JPRAS
  • [ISO-abbreviation] J Plast Reconstr Aesthet Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


55. Zambelli A, Lilleri D, Baldanti F, Scelsi M, Villani L, Da Prada GA: Hodgkin's disease as unusual presentation of post-transplant lymphoproliferative disorder after autologous hematopoietic cell transplantation for malignant glioma. BMC Cancer; 2005;5:109
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin's disease as unusual presentation of post-transplant lymphoproliferative disorder after autologous hematopoietic cell transplantation for malignant glioma.
  • BACKGROUND: Post-transplant lymphoproliferative disorder (PTLD) is a complication of solid organ and allogeneic hematopoietic stem cell transplantation (HSCT); following autologous HSCT only rare cases of PTLD have been reported.
  • Here, a case of Hodgkin's disease (HD), as unusual presentation of PTLD after autologous HSCT for malignant glioma is described.
  • At day +105 after HSCT, the patient developed HD, nodular sclerosis type, with polymorphic HD-like skin infiltration.
  • [MeSH-major] Glioma / therapy. Hematopoietic Stem Cell Transplantation / adverse effects. Hodgkin Disease / diagnosis. Lymphoproliferative Disorders / etiology. Transplantation, Homologous / adverse effects

  • Genetic Alliance. consumer health - Glioma.
  • Genetic Alliance. consumer health - Post-transplant lymphoproliferative disease.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leuk Lymphoma. 2000 Sep;39(1-2):195-201 [10975399.001]
  • [Cites] Semin Oncol. 1999 Oct;26(5 Suppl 14):21-5 [10561014.001]
  • [Cites] J Clin Microbiol. 2000 Feb;38(2):613-9 [10655355.001]
  • [Cites] Bone Marrow Transplant. 2000 Dec;26(12):1339-41 [11223975.001]
  • [Cites] Bone Marrow Transplant. 2002 Sep;30(5):321-6 [12209355.001]
  • [Cites] N Engl J Med. 1989 Oct 19;321(16):1080-5 [2552313.001]
  • [Cites] J Clin Oncol. 1999 Oct;17(10):3122-7 [10506608.001]
  • [Cites] Bone Marrow Transplant. 1995 Apr;15(4):639-41 [7655394.001]
  • [Cites] Semin Diagn Pathol. 1997 Feb;14(1):8-14 [9044505.001]
  • [Cites] Br J Haematol. 1997 Aug;98(2):485-7 [9266955.001]
  • [Cites] Blood. 1998 Mar 15;91(6):1833-44 [9490664.001]
  • [Cites] Bone Marrow Transplant. 1998 Jun;21(12):1271-4 [9674863.001]
  • [Cites] Bone Marrow Transplant. 1998 Aug;22(3):307-9 [9720750.001]
  • [Cites] Transplantation. 1993 Jun;55(6):1425-8 [8390736.001]
  • (PMID = 16117828.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC1208867
  •  go-up   go-down


56. Tomoyose T, Nagasaki A, Uchihara JN, Kinjo S, Sugaya K, Onaga T, Ohshima K, Masuda M, Takasu N: Primary adrenal adult T-cell leukemia/lymphoma: a case report and review of the literature. Am J Hematol; 2007 Aug;82(8):748-52
MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary adrenal adult T-cell leukemia/lymphoma: a case report and review of the literature.
  • Primary adrenal lymphoma (PAL) is very rare; the majority of cases reported previously were of B-cell origin.
  • We report a rare case of primary adrenal adult T-cell leukemia/lymphoma (primary adrenal ATLL).
  • ATLL is a highly aggressive T-cell type non-Hodgkin's lymphoma and etiologically associated with human T-cell lymphotropic virus 1 (HTLV-1).
  • Examination showed no peripheral lymphadenopathy, circulating lymphoma cells, hepatosplenomegaly, and skin lesions.
  • Subsequently, she underwent open adrenal biopsy and pathological diagnosis was confirmed as T-cell lymphoma.
  • [MeSH-major] Adrenal Gland Neoplasms / pathology. Leukemia-Lymphoma, Adult T-Cell / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17373678.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 34
  •  go-up   go-down


57. Gardner JM, Evans KG, Musiek A, Rook AH, Kim EJ: Update on treatment of cutaneous T-cell lymphoma. Curr Opin Oncol; 2009 Mar;21(2):131-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Update on treatment of cutaneous T-cell lymphoma.
  • PURPOSE OF REVIEW: Cutaneous T-cell lymphomas (CTCLs) are a heterogenous group of non-Hodgkin's lymphomas characterized by atypical, skin-homing T lymphocytes and have varying prognoses depending on subtype and disease stage.
  • Also, several novel skin-directed treatments and systemic compounds have been studied in all CTCL stages as well as in treatment-refractory disease.
  • [MeSH-major] Lymphoma, T-Cell, Cutaneous / therapy. Skin Neoplasms / therapy
  • [MeSH-minor] Alkylating Agents / administration & dosage. Anticarcinogenic Agents / administration & dosage. Combined Modality Therapy. Humans. Immunologic Factors / administration & dosage. Phototherapy. Skin / drug effects. Stem Cell Transplantation. Treatment Outcome

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19532014.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Alkylating Agents; 0 / Anticarcinogenic Agents; 0 / Immunologic Factors
  • [Number-of-references] 63
  •  go-up   go-down


58. Shimizu I, Ichikawa N, Yotsumoto M, Sumi M, Ueno M, Kobayashi H: Asian variant of intravascular lymphoma: aspects of diagnosis and the role of rituximab. Intern Med; 2007;46(17):1381-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Asian variant of intravascular lymphoma: aspects of diagnosis and the role of rituximab.
  • OBJECTIVE: The Asian variant of intravascular lymphoma (AIVL) is a rare non-Hodgkin's lymphoma, characterized by hemophagocytic syndrome and the absence of neurological abnormality or skin lesions, which are typical features of classical IVL.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, Large B-Cell, Diffuse / diagnosis. Vascular Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17827836.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


59. Bauer A, Perras B, Sufke S, Horny HP, Kreft B: Myocardial infarction as an uncommon clinical manifestation of intravascular large cell lymphoma. Acta Cardiol; 2005 Oct;60(5):551-5
MedlinePlus Health Information. consumer health - Heart Attack.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myocardial infarction as an uncommon clinical manifestation of intravascular large cell lymphoma.
  • Intravascular large cell lymphoma (IVL) is a very rare variant of non-Hodgkin's lymphoma presenting with puzzling clinical manifestations.
  • There is a predilection for the central nervous system, but the tumour often affects also skin, lung, and kidneys while lymphadenopathy and hepatosplenomegaly are usually absent.
  • Autopsy revealed a generalized high-grade B cell lymphoma of IVL type affecting and obstructing small vessels of a variety of tissues including heart, brain and lungs.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / complications. Myocardial Infarction / etiology. Shock, Cardiogenic / etiology. Vascular Neoplasms / complications

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16261789.001).
  • [ISSN] 0001-5385
  • [Journal-full-title] Acta cardiologica
  • [ISO-abbreviation] Acta Cardiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


60. Chao-Lo MP, King-Ismael D, Lopez RA: Primary cutaneous CD30+ anaplastic large cell lymphoma: report of a rare case. J Dermatol Case Rep; 2008 Oct 11;2(3):31-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous CD30+ anaplastic large cell lymphoma: report of a rare case.
  • Primary cutaneous anaplastic large cell lymphoma (PCALCL) is a rare type of non-Hodgkin's lymphoma comprising approximately 0.9-9.0% of all cutaneous lymphomas.
  • Skin punch biopsy revealed dense infiltrates of non-epidermotropic, large, irregularly-shaped lymphocytes with hyperchromatic and pyknotic nuclei.
  • Immunohistochemistry revealed that these atypical cells are anaplastic lymphoma kinase (ALK) positive, CD30+, CD3-, CD20- and epithelial membrane antigen (EMA) negative.
  • Short course CHOP (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) chemotherapy resulted in total resolution of skin lesions; however, recurrence was noted 12 months after treatment.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Acad Dermatol. 1999 May;40(5 Pt 2):857-61 [10321635.001]
  • [Cites] Eur J Pediatr. 2008 Jan;167(1):111-3 [17219127.001]
  • [Cites] J Am Acad Dermatol. 2000 Nov;43(5 Pt 1):793-6 [11050582.001]
  • [Cites] Blood. 2000 Dec 1;96(12):3681-95 [11090048.001]
  • [Cites] Am J Dermatopathol. 2003 Apr;25(2):142-7 [12652196.001]
  • [Cites] J Am Acad Dermatol. 2003 Dec;49(6):1049-58 [14639383.001]
  • [Cites] Blood. 2005 May 15;105(10):3768-85 [15692063.001]
  • [Cites] Pediatr Dev Pathol. 2005 Jan-Feb;8(1):52-60 [15719203.001]
  • [Cites] Indian J Dermatol Venereol Leprol. 2004 May-Jun;70(3):168-71 [17642599.001]
  • [Cites] Blood. 2007 Jul 15;110(2):479-84 [17339420.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Dec;17(6):1319-32, vii-viii [14710887.001]
  • [Cites] Pediatr Dermatol. 2004 May-Jun;21(3):212-7 [15165197.001]
  • [Cites] Br J Dermatol. 2004 Jun;150(6):1202-7 [15214912.001]
  • [Cites] J Am Acad Dermatol. 2004 Jul;51(1):103-10 [15243534.001]
  • [Cites] Eur J Haematol. 2005 Sep;75(3):221-6 [16104878.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2006;:323-30, 513 [17124079.001]
  • [Cites] Am J Dermatopathol. 2000 Oct;22(5):422-8 [11048978.001]
  • (PMID = 21886709.001).
  • [ISSN] 1898-7249
  • [Journal-full-title] Journal of dermatological case reports
  • [ISO-abbreviation] J Dermatol Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Other-IDs] NLM/ PMC3157779
  • [Keywords] NOTNLM ; lymphomatoid papulosis / lymphoproliferative disorders / mycosis fungoides / primary cutaneous CD30 positive large T cell lymphoma / primary cutaneous anaplastic large cell lymphoma
  •  go-up   go-down


61. Gellrich S, Muche JM, Wilks A, Jasch KC, Voit C, Fischer T, Audring H, Sterry W: Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation. Br J Dermatol; 2005 Jul;153(1):167-73
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.
  • BACKGROUND: Primary cutaneous B-cell lymphomas (PCBCLs) are characterized by restriction to the skin and a variable but mostly favourable prognosis.
  • Since 1997 the recombinant, chimeric anti-CD20 antibody rituximab has been used in patients suffering from non-Hodgkin's B-cell lymphomas.
  • Different studies have shown that the effectiveness and safety in the treatment of patients with low-grade follicular lymphoma is comparable to or even higher than the standard CHOP chemotherapy.
  • PATIENTS/METHODS: Ten patients with PCBCL [eight with follicle centre cell lymphoma (FCCL), one with marginal zone lymphoma (MZL) and one with diffuse large B-cell lymphoma of the leg (DLBCL)] were treated by intravenous application of a chimeric antibody against the CD20 transmembrane antigen (rituximab) with a dosage of eight cycles, 375 mg m(-2) body surface, weekly.
  • As expected the B-cell count in peripheral blood was depressed in all patients after infusion.
  • CONCLUSIONS: Intravenous therapy with eight cycles of the anti-CD20 antibody rituximab is a non-toxic and effective treatment for a subset of patients with PCBCL (relapsed, aggressive entity, old patients, multiple lesions) with a long DR.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, B-Cell / drug therapy. Skin Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Cutaneous B-Cell Lymphomas.
  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16029344.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 28
  •  go-up   go-down


62. Verma NK, Davies AM, Long A, Kelleher D, Volkov Y: STAT3 knockdown by siRNA induces apoptosis in human cutaneous T-cell lymphoma line Hut78 via downregulation of Bcl-xL. Cell Mol Biol Lett; 2010 Jun;15(2):342-55
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] STAT3 knockdown by siRNA induces apoptosis in human cutaneous T-cell lymphoma line Hut78 via downregulation of Bcl-xL.
  • Cutaneous T-cell lymphomas (CTCLs) are non-Hodgkin's lymphomas resulting from clonal expansion and localization of malignant T-lymphocytes to the skin.
  • Signal transducers and activators of transcription (STAT) are a family of transcription factors known to play important roles in the development and progression of several human cancers by promoting cell proliferation and protecting against apoptosis.
  • In this study, we investigated the specific role of STAT3, a major component of the STAT family, in growth and survival of human CTCL cell line Hut78.
  • Specific knockdown of STAT3 expression in Hut78 cells by RNA interference induced morphological and biochemical changes indicating apoptotic cell death.
  • [MeSH-major] Apoptosis. Gene Knockdown Techniques. Lymphoma, T-Cell, Cutaneous / pathology. RNA, Small Interfering / metabolism. STAT3 Transcription Factor / metabolism. Skin Neoplasms / pathology. bcl-X Protein / metabolism
  • [MeSH-minor] Cell Line, Tumor. Cell Proliferation. Down-Regulation. Humans

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20213502.001).
  • [ISSN] 1689-1392
  • [Journal-full-title] Cellular & molecular biology letters
  • [ISO-abbreviation] Cell. Mol. Biol. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / RNA, Small Interfering; 0 / STAT3 Transcription Factor; 0 / STAT3 protein, human; 0 / bcl-X Protein
  •  go-up   go-down


63. Ferdinand RF: Validity of the CBCL/YSR DSM-IV scales Anxiety Problems and Affective Problems. J Anxiety Disord; 2008;22(1):126-34
MedlinePlus Health Information. consumer health - Mood Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Validity of the CBCL/YSR DSM-IV scales Anxiety Problems and Affective Problems.
  • BACKGROUND: The Child Behavior Checklist (CBCL) and Youth Self-Report (YSR) are widely used for clinical and research purposes.
  • METHODS: In a referred sample of 277 6- to 18-year-olds, it was examined to what extent CBCL/YSR scores on the Anxiety Problems and Affective Problems scale predicted DSM-IV diagnoses of separation anxiety disorder, generalized anxiety disorder, specific phobia, major depressive disorder, or dysthymia.
  • RESULTS: Scores on the CBCL and YSR Anxiety Problems scale predicted DSM-IV disorders only moderately.
  • However, CBCL and YSR scores on the Affective Problems scale corresponded closely to DSM-IV major depressive disorder and dysthymia.
  • DISCUSSION: Scores on the CBCL/YSR Affective Problems scale can be used to screen for DSM-IV affective disorders.
  • The item content of the CBCL/YSR Anxiety Problems scale requires renewed attention.

  • Genetic Alliance. consumer health - Anxiety.
  • MedlinePlus Health Information. consumer health - Anxiety.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17321103.001).
  • [ISSN] 0887-6185
  • [Journal-full-title] Journal of anxiety disorders
  • [ISO-abbreviation] J Anxiety Disord
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] United States
  •  go-up   go-down


64. Prajapati V, Mydlarski PR: Rituximab: a B-cell depletion therapy for dermatologic disease. Skin Therapy Lett; 2007 Jul-Aug;12(6):6-9
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab: a B-cell depletion therapy for dermatologic disease.
  • Initially approved for the treatment of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma (NHL), rituximab has been increasingly used to treat a variety of immune-mediated and autoimmune diseases.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. B-Lymphocytes / immunology. Immunologic Factors / therapeutic use. Lymphocyte Depletion / methods. Skin Diseases / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Autoimmune Diseases / drug therapy. Humans. Lymphoma, B-Cell / drug therapy. Rituximab. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17762903.001).
  • [ISSN] 1201-5989
  • [Journal-full-title] Skin therapy letter
  • [ISO-abbreviation] Skin Therapy Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Immunologic Factors; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 31
  •  go-up   go-down


65. Polder K, Wang C, Duvic M, Diwan AH, Parks D, Jankov A, Walker PL, Tong AT, Bull J, Dang NH: Toxic epidermal necrolysis associated with denileukin diftitox (DAB389IL-2) administration in a patient with follicular large cell lymphoma. Leuk Lymphoma; 2005 Dec;46(12):1807-11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Toxic epidermal necrolysis associated with denileukin diftitox (DAB389IL-2) administration in a patient with follicular large cell lymphoma.
  • Denileukin diftitox (DAB(389)IL-2 or Ontak) is a synthetic fusion protein with demonstrated efficacy in a number of lymphoproliferative disorders, including non-Hodgkin's lymphoma.
  • We report the case of a 45-year-old man with progressive follicular large cell lymphoma following an autologous stem cell transplant treated with denileukin diftitox who developed a fatal skin rash associated with extensive erythema, edema and large bullae involving his entire body.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Diphtheria Toxin / adverse effects. Interleukin-2 / adverse effects. Lymphoma, Follicular / drug therapy. Stevens-Johnson Syndrome / pathology

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16263585.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Diphtheria Toxin; 0 / Interleukin-2; 0 / Recombinant Fusion Proteins; 25E79B5CTM / denileukin diftitox
  •  go-up   go-down


66. McGough JJ, Loo SK, McCracken JT, Dang J, Clark S, Nelson SF, Smalley SL: CBCL pediatric bipolar disorder profile and ADHD: comorbidity and quantitative trait loci analysis. J Am Acad Child Adolesc Psychiatry; 2008 Oct;47(10):1151-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CBCL pediatric bipolar disorder profile and ADHD: comorbidity and quantitative trait loci analysis.
  • OBJECTIVE: The pediatric bipolar disorder profile of the Child Behavior Checklist (CBCL-PBD), a parent-completed measure that avoids clinician ideological bias, has proven useful in differentiating patients with attention-deficit/hyperactivity disorder (ADHD).
  • We used CBCL-PBD profiles to distinguish patterns of comorbidity and to search for quantitative trait loci in a genomewide scan in a sample of multiple affected ADHD sibling pairs.
  • METHOD: A total of 540 ADHD subjects ages 5 to 18 years were assessed with the Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime version and CBCL.
  • Patterns of psychiatric comorbidity were contrasted based on the CBCL-PBD profile.
  • A quantitative trait loci variance component analysis was used to identify potential genomic regions that may harbor susceptibility genes for the CBCL-PBD quantitative phenotype.
  • The CBCL-PBD classification was associated with increased generalized anxiety disorder (p =.001), oppositional defiant disorder (p =.008), conduct disorder (p =.003), and parental substance abuse (p =.005).
  • CONCLUSIONS: The CBCL-PBD profile distinguishes a subset of ADHD patients with significant comorbidity.
  • Linkage analysis of the CBCL-PBD phenotype suggests certain genomic regions that merit further investigation for genes predisposing to severe psychopathology.

  • Genetic Alliance. consumer health - Bipolar Disorder.
  • MedlinePlus Health Information. consumer health - Attention Deficit Hyperactivity Disorder.
  • MedlinePlus Health Information. consumer health - Bipolar Disorder.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Biol. 2000 Feb;72(1):35-62 [10721613.001]
  • [Cites] Bipolar Disord. 2007 Dec;9(8):895-900 [18076540.001]
  • [Cites] Hum Hered. 2000 Jul-Aug;50(4):251-6 [10782019.001]
  • [Cites] Nature. 2000 Jun 15;405(6788):847-56 [10866211.001]
  • [Cites] Am J Med Genet. 2000 Jun 12;96(3):241-3 [10898892.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 2000 Sep;39(9):1135-43 [10986810.001]
  • [Cites] Psychiatry Res. 2001 Feb 14;101(1):47-54 [11223119.001]
  • [Cites] Am J Hum Genet. 2002 May;70(5):1183-96 [11923911.001]
  • [Cites] J Psychiatr Res. 2002 Sep-Oct;36(5):337-45 [12127602.001]
  • [Cites] Am J Hum Genet. 2002 Oct;71(4):959-63 [12187510.001]
  • [Cites] Am J Psychiatry. 2003 Mar;160(3):430-7 [12611821.001]
  • [Cites] Am J Hum Genet. 2003 May;72(5):1268-79 [12687500.001]
  • [Cites] Biol Psychiatry. 2003 Jun 1;53(11):1021-7 [12788247.001]
  • [Cites] Hum Mutat. 2003 Oct;22(4):261-74 [12955713.001]
  • [Cites] Mol Psychiatry. 2004 May;9(5):485-93 [14625563.001]
  • [Cites] Am J Hum Genet. 2004 Oct;75(4):661-8 [15297934.001]
  • [Cites] Arch Gen Psychiatry. 1982 Aug;39(8):879-83 [7103676.001]
  • [Cites] J Psychiatr Res. 1986;20(4):317-25 [3806426.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 1995 Apr;34(4):464-71 [7751260.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 1995 Jul;34(7):867-76 [7649957.001]
  • [Cites] Nat Genet. 1995 Nov;11(3):241-7 [7581446.001]
  • [Cites] Am J Hum Genet. 1997 Jun;60(6):1276-82 [9199546.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 1997 Jul;36(7):980-8 [9204677.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 1997 Sep;36(9):1168-76 [9291717.001]
  • [Cites] J Paediatr Child Health. 1999 Apr;35(2):199-203 [10365361.001]
  • [Cites] J Affect Disord. 2004 Oct;82 Suppl 1:S59-69 [15571791.001]
  • [Cites] Am J Psychiatry. 2005 Jan;162(1):3-11 [15625194.001]
  • [Cites] Am J Psychiatry. 2005 Sep;162(9):1614-20 [16135619.001]
  • [Cites] Am J Psychiatry. 2005 Sep;162(9):1621-7 [16135620.001]
  • [Cites] Arch Dis Child. 2005 Oct;90(10):1010-5 [16177156.001]
  • [Cites] Biol Psychiatry. 2005 Oct 1;58(7):576-82 [16084859.001]
  • [Cites] Biol Psychiatry. 2005 Oct 1;58(7):583-8 [16197929.001]
  • [Cites] Biol Psychiatry. 2005 Oct 1;58(7):562-8 [16239161.001]
  • [Cites] Bipolar Disord. 2005 Dec;7(6):518-24 [16403177.001]
  • [Cites] Biol Psychiatry. 2006 Nov 1;60(9):903-11 [16650832.001]
  • [Cites] Dev Psychopathol. 2006 Fall;18(4):939-69 [17064424.001]
  • [Cites] Behav Genet. 2007 Jul;37(4):559-66 [17443404.001]
  • [Cites] Biol Psychiatry. 2007 Jul 15;62(2):115-20 [16950211.001]
  • [Cites] Biol Psychiatry. 2007 Jul 15;62(2):107-14 [17306773.001]
  • [Cites] Am J Hum Genet. 2007 Nov;81(5):974-86 [17924339.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 2007 Dec;46(12):1575-83 [18030079.001]
  • [Cites] J Affect Disord. 1998 Nov;51(2):93-100 [10743842.001]
  • (PMID = 18724256.001).
  • [ISSN] 1527-5418
  • [Journal-full-title] Journal of the American Academy of Child and Adolescent Psychiatry
  • [ISO-abbreviation] J Am Acad Child Adolesc Psychiatry
  • [Language] ENG
  • [Grant] United States / NIMH NIH HHS / MH / MH58277; United States / NIMH NIH HHS / MH / R01 MH071852-01A2; United States / NICHD NIH HHS / HD / K23 HD040275-01A1; United States / NIMH NIH HHS / MH / R01 MH058277; United States / NIMH NIH HHS / MH / K24 MH001805-01A2; United States / NIMH NIH HHS / MH / MH001966-01; United States / NIMH NIH HHS / MH / R01 MH071852; United States / NIMH NIH HHS / MH / MH071852; United States / NIMH NIH HHS / MH / K23 MH001966-01; United States / NICHD NIH HHS / HD / K23 HD040275; United States / NIMH NIH HHS / MH / MH001805-01A2; United States / NIMH NIH HHS / MH / R01 MH058277-02; United States / NIMH NIH HHS / MH / MH01969; United States / NIMH NIH HHS / MH / K23 MH001966; United States / NICHD NIH HHS / HD / HD040275-01A1; United States / NIMH NIH HHS / MH / MH01805; United States / NICHD NIH HHS / HD / HD40275; United States / NIMH NIH HHS / MH / K24 MH001805; United States / NIMH NIH HHS / MH / MH058277-02; United States / NIMH NIH HHS / MH / MH071852-01A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS84652; NLM/ PMC2783759
  •  go-up   go-down


67. Lanoy E, Engels EA: Skin cancers associated with autoimmune conditions among elderly adults. Br J Cancer; 2010 Jun 29;103(1):112-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skin cancers associated with autoimmune conditions among elderly adults.
  • BACKGROUND: Immunosuppression is a risk factor for certain skin cancers.
  • Autoimmune conditions can involve the skin, and may involve immunosuppressive therapies.
  • METHODS: We conducted a population-based case-control study among elderly US adults using Surveillance, Epidemiology, and End Results-Medicare-linked data of 44,613 skin cancer cases and 178,452 frequency-matched controls.
  • RESULTS: The most frequent autoimmune condition was rheumatoid arthritis (2.29%), which was associated with slightly increased risk of Merkel cell carcinoma (N=1977; OR (95%CI): 1.39 (1.10-1.74)).
  • Risk of cutaneous non-Hodgkin's lymphoma (N=2652) was increased with psoriasis (OR (95%CI): 3.20 (2.62-3.92)).
  • CONCLUSIONS: These findings suggest that immune disturbances in the skin, arising from autoimmune conditions or their treatment, promote development of skin cancer.
  • [MeSH-major] Autoimmune Diseases / complications. Skin Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Acad Dermatol. 2001 May;44(5):755-61 [11312420.001]
  • [Cites] Br J Math Stat Psychol. 2002 May;55(Pt 1):27-39 [12034010.001]
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-3-18 [12187163.001]
  • [Cites] Br J Cancer. 1989 May;59(5):810-3 [2736218.001]
  • [Cites] Int J Cancer. 2010 Apr 1;126(7):1724-31 [19810102.001]
  • [Cites] Blood. 2008 Apr 15;111(8):4029-38 [18263783.001]
  • [Cites] Dis Colon Rectum. 2009 Jan;52(1):154-8 [19273971.001]
  • [Cites] Int J Hematol. 2009 May;89(4):523-8 [19381762.001]
  • [Cites] Int J Cancer. 2009 Jul 15;125(2):398-405 [19365835.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Sep;16(9):1840-4 [17855703.001]
  • (PMID = 20551958.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 CP010150-08
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS210844; NLM/ PMC2894998
  •  go-up   go-down


68. Holtmann M, Goth K, Wöckel L, Poustka F, Bölte S: CBCL-pediatric bipolar disorder phenotype: severe ADHD or bipolar disorder? J Neural Transm (Vienna); 2008;115(2):155-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CBCL-pediatric bipolar disorder phenotype: severe ADHD or bipolar disorder?
  • BACKGROUND: In children with pediatric bipolar disorder (PBD), a consistent pattern of elevations in hyperactivity, depression/anxiety, and aggression has been identified on the child behavior checklist (CBCL-PBD profile).
  • The aim of the present study was to estimate the prevalence of the CBCL-PBD profile in a child psychiatric sample, and to determine ICD-10 diagnoses in CBCL-PBD patients.
  • The CBCL 4-18 was completed by parents as part of the diagnostic routine.
  • RESULTS: A total of 62 subjects (6.6%; 95% CI=5.2-8.4) met criteria for the CBCL-PBD phenotype.
  • More than 75% of CBCL-PBD subjects were clinically diagnosed with disruptive behavior disorders (ADHD, ODD, and CD).
  • Two patients (0.2% of the total sample) received a formal diagnosis of bipolar disorder, but did not show the CBCL-PBD phenotype.
  • However, the CBCL-PBD phenotype does not correspond with clinical consensus diagnoses of bipolar disorder, but with severe disruptive behavior disorders.


69. Sikora DM, Hall TA, Hartley SL, Gerrard-Morris AE, Cagle S: Does parent report of behavior differ across ADOS-G classifications: analysis of scores from the CBCL and GARS. J Autism Dev Disord; 2008 Mar;38(3):440-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does parent report of behavior differ across ADOS-G classifications: analysis of scores from the CBCL and GARS.
  • The usefulness of two behavioral checklists, the Gilliam Autism Rating Scale (GARS) and Child Behavior Checklist (CBCL), in identifying ASDs was investigated among 109 children with Autism, 32 children with ASD, and 51 Non-Spectrum children based on Autism Diagnostic Observation Schedule-Generic classifications.
  • The Withdrawn and Pervasive Developmental Problems subscales of the CBCL were higher among children with Autism than among Non-Spectrum children.
  • These CBCL subscales also had better sensitivity and specificity in identifying children with Autism than the GARS.
  • Results suggest that the CBCL is a useful behavioral checklist for screening ASDs.

  • MedlinePlus Health Information. consumer health - Child Behavior Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Autism Dev Disord. 2002 Dec;32(6):593-9 [12553595.001]
  • [Cites] J Autism Dev Disord. 2000 Jun;30(3):205-23 [11055457.001]
  • [Cites] J Autism Dev Disord. 2003 Dec;33(6):703-7 [14714937.001]
  • [Cites] Health Serv Res. 2005 Oct;40(5 Pt 2):1605-19 [16178998.001]
  • [Cites] J Clin Child Adolesc Psychol. 2005 Sep;34(3):523-40 [16083393.001]
  • [Cites] J Autism Dev Disord. 1999 Jun;29(3):235-48 [10425586.001]
  • [Cites] Arch Pediatr Adolesc Med. 1994 Feb;148(2):174-9 [8118536.001]
  • (PMID = 17619131.001).
  • [ISSN] 0162-3257
  • [Journal-full-title] Journal of autism and developmental disorders
  • [ISO-abbreviation] J Autism Dev Disord
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Pantanowitz L, Schlecht HP, Dezube BJ: The growing problem of non-AIDS-defining malignancies in HIV. Curr Opin Oncol; 2006 Sep;18(5):469-78
HIV InSite. treatment guidelines - Coinfection with Hepatitis Viruses and HIV .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The growing problem of non-AIDS-defining malignancies in HIV.
  • PURPOSE OF REVIEW: The incidence and spectrum of non-AIDS-defining cancers has continued to grow.
  • The recent literature pertaining to non-AIDS-defining cancers is reviewed.
  • RECENT FINDINGS: Recent epidemiological studies have identified higher rates of carcinoma of the anus, lung, breast, skin, conjunctiva, liver and prostate; hematopoietic malignancies such as Hodgkin's lymphoma, plasma-cell neoplasia and leukemia; and other neoplasms like melanoma and leiomyosarcoma in HIV-positive patients.
  • The role of HIV-induced immunosuppression in the development of these non-AIDS-defining cancers appears less important than lifestyle habits like smoking and sun exposure, as well as coinfection with human papilloma, hepatitis B, hepatitis C and Epstein-Barr viruses.
  • SUMMARY: It is unclear whether the growing number of reports on non-AIDS-defining cancers reflects a true increased incidence or merely the product of increased surveillance, detection and reporting.
  • Highly active antiretroviral therapy not only promotes longevity in the HIV-positive population, but may increase their risk of developing cancer like Hodgkin's lymphoma.
  • Assertive prevention strategies are needed to adequately deal with non-AIDS-defining cancers in an aging and growing HIV-positive population.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16894295.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / P30 AI 060354
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents
  • [Number-of-references] 95
  •  go-up   go-down


71. Meyer SE, Carlson GA, Youngstrom E, Ronsaville DS, Martinez PE, Gold PW, Hakak R, Radke-Yarrow M: Long-term outcomes of youth who manifested the CBCL-Pediatric Bipolar Disorder phenotype during childhood and/or adolescence. J Affect Disord; 2009 Mar;113(3):227-35
MedlinePlus Health Information. consumer health - Bipolar Disorder.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcomes of youth who manifested the CBCL-Pediatric Bipolar Disorder phenotype during childhood and/or adolescence.
  • OBJECTIVE: Recent studies have identified a Child Behavior Checklist (CBCL) profile that characterizes children with severe aggression, inattention, and mood instability.
  • This profile has been coined the CBCL-Pediatric Bipolar Disorder (PBD) phenotype, because it is commonly seen among children with bipolar disorder.
  • However, mounting evidence suggests that the CBCL-PBD may be a better tool for identifying children with severe functional impairment and broad-ranging psychiatric comorbidities rather than bipolar disorder itself.
  • No studies have followed individuals with the CBCL-PBD profile through adulthood, so its long-term implications remain unclear.
  • The present authors examined diagnostic and functional trajectories of individuals with the CBCL-PBD profile from early childhood through young adulthood using data from a longitudinal high-risk study.
  • RESULTS: Across development, participants with the CBCL-PBD phenotype exhibited marked psychosocial impairment, increased rates of suicidal thoughts and behaviors and heightened risk for comorbid anxiety, bipolar disorder, cluster B personality disorders and ADHD in young adulthood, compared to participants without this presentation.
  • CONCLUSIONS: Children with the CBCL-PBD profile are at risk for ongoing, severe, psychiatric symptomatology including behavior and emotional comorbidities in general, and bipolar disorder, anxiety, ADHD, cluster B personality disorders in particular.

  • Genetic Alliance. consumer health - Bipolar Disorder.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18632161.001).
  • [ISSN] 1573-2517
  • [Journal-full-title] Journal of affective disorders
  • [ISO-abbreviation] J Affect Disord
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] Netherlands
  •  go-up   go-down


72. Albores-Gallo L, Lara-Muñoz C, Esperón-Vargas C, Cárdenas Zetina JA, Pérez Soriano AM, Villanueva Colin G: Validity and reability of the CBCL/6-18. Includes DSM scales. Actas Esp Psiquiatr; 2007 Nov-Dec;35(6):393-9
MedlinePlus Health Information. consumer health - Child Behavior Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Validity and reability of the CBCL/6-18. Includes DSM scales.
  • INTRODUCTION: The Child Behavior Checklist (CBCL/6-18) is the most commonly used parent-completed instrument that assesses child and adolescent psychopathology.
  • OBJECTIVE: Investigate the psychometric properties of the CBCL/6-18 and develops a valid and reliable Mexican version.
  • METHOD: Psychologists and child psychiatrists adapted the Spanish version of CBCL/6-18, and a back translation was done by a native English speaker.
  • A ROC curve was performed to estimate a cut-off which correctly identified children from the clinically referred patients and children recruited in the community (non-referred).
  • RESULTS: The Mexican version of the CBCL/6-18 showed that the Cronbach's alpha coefficient was 0.90 for internalizing problems, 0.94 for externalizing problems and 0.97 for the total problem scale.
  • CONCLUSIONS: The Mexican version of CBCL/6-18 is a reliable and valid screening instrument for clinical and epidemiologic use.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18004676.001).
  • [ISSN] 1139-9287
  • [Journal-full-title] Actas españolas de psiquiatría
  • [ISO-abbreviation] Actas Esp Psiquiatr
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] Spain
  •  go-up   go-down


73. Boomsma DI, Rebollo I, Derks EM, van Beijsterveldt TC, Althoff RR, Rettew DC, Hudziak JJ: Longitudinal stability of the CBCL-juvenile bipolar disorder phenotype: A study in Dutch twins. Biol Psychiatry; 2006 Nov 1;60(9):912-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Longitudinal stability of the CBCL-juvenile bipolar disorder phenotype: A study in Dutch twins.
  • BACKGROUND: The Child Behavior Checklist-juvenile bipolar disorder phenotype (CBCL-JBD) is a quantitative phenotype that is based on parental ratings of the behavior of the child.
  • The purpose of this study is to assess the developmental stability of the CBCL-JBD phenotype across ages 7, 10, and 12 years in a large population-based twin sample and to examine its genetic architecture.
  • METHODS: Longitudinal data on Dutch mono- and dizygotic twin pairs (N = 8013 pairs) are analyzed to decompose the stability of the CBCL-JBD phenotype into genetic and environmental contributions.
  • RESULTS: Heritability of the CBCL-JBD increases with age (from 63% to 75%), whereas the effects of shared environment decrease (from 20% to 8%).
  • The stability of the CBCL-JBD phenotype is high, with correlations between .66 and .77 across ages 7, 10, and 12 years.
  • CONCLUSIONS: Roughly 80% of the stability in childhood CBCL-JBD is a result of additive genetic effects.

  • Genetic Alliance. consumer health - Bipolar Disorder.
  • MedlinePlus Health Information. consumer health - Bipolar Disorder.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16735031.001).
  • [ISSN] 0006-3223
  • [Journal-full-title] Biological psychiatry
  • [ISO-abbreviation] Biol. Psychiatry
  • [Language] eng
  • [Grant] United States / NIMH NIH HHS / MH / MH58799
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


74. Faraone SV, Althoff RR, Hudziak JJ, Monuteaux M, Biederman J: The CBCL predicts DSM bipolar disorder in children: a receiver operating characteristic curve analysis. Bipolar Disord; 2005 Dec;7(6):518-24
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The CBCL predicts DSM bipolar disorder in children: a receiver operating characteristic curve analysis.
  • The CBCL-PBD profile on the Child Behavior Checklist (CBCL) has been consistently reported showing deviant findings on the Attention Problems, Aggressive Behavior, and Anxious-Depressed subscales.
  • AIM: To examine the sensitivity and specificity of the proposed CBCL-PBD profile for determining DSM diagnosis of PBD.
  • RESULTS: The CBCL-PBD score demonstrated an area under the curve (AUC) of 0.97 for probands and 0.82 for siblings for current diagnosis of PBD, suggesting that the CBCL-PBD provided a highly efficient way of identifying subjects with a current diagnosis of PBD in this sample.
  • CONCLUSIONS: These findings suggest that the CBCL-PBD may provide a highly efficient way of screening for childhood bipolar disorder.

  • Genetic Alliance. consumer health - Bipolar Disorder.
  • MedlinePlus Health Information. consumer health - Bipolar Disorder.
  • MedlinePlus Health Information. consumer health - Child Behavior Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16403177.001).
  • [ISSN] 1398-5647
  • [Journal-full-title] Bipolar disorders
  • [ISO-abbreviation] Bipolar Disord
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / R01HD37999; United States / NIMH NIH HHS / MH / R01MH66877
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  •  go-up   go-down


75. Bhanot UK, Rauniyar SK, Mital VP: Fine needle aspiration cytology of metastatic skin nodules. A report of 2 cases. Acta Cytol; 2007 Jan-Feb;51(1):95-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine needle aspiration cytology of metastatic skin nodules. A report of 2 cases.
  • BACKGROUND: Skin is an uncommon site for metastatic deposits from internal malignancy.
  • Metastatic skin/scalp nodules can be diagnosed accurately by fine needle aspiration cytology (FNAC).
  • However, few reports exist on the FNAC diagnosis of metastatic skin/scalp nodules.
  • Metastatic skin nodules may mimic primary skin tumors, or vice versa, and some primary skin tumors may be mistaken for metastatic skin deposits.
  • FNAC of the scalp nodule and cervical lymph nodes revealed the cytologic features of non-Hodgkin's lymphoma.
  • CONCLUSION: Metastatic cutaneous/staneous/subcutaneous deposits can pose diagnostic hurdles in the absence ofprevious or simultaneous malignancy.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Lymphoma, Non-Hodgkin / pathology. Scalp. Skin Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17328506.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Whittaker S: Biological insights into the pathogenesis of cutaneous T-cell lymphomas (CTCL). Semin Oncol; 2006 Feb;33(1 Suppl 3):S3-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biological insights into the pathogenesis of cutaneous T-cell lymphomas (CTCL).
  • Mycosis fungoides and Sezary syndrome, collectively known as cutaneous T-cell lymphomas (CTCLs), are low-grade, indolent, clonal, non-Hodgkin's lymphomas consisting of CD4+ CD45RO+ T cells with a CLA+ CCR4+ skin-homing phenotype.
  • There are several variants of primary CTCLs with differences in clinical behavior and prognosis.
  • [MeSH-major] Lymphoma, T-Cell, Cutaneous / etiology. Skin Neoplasms / etiology

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16516668.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 20
  •  go-up   go-down


77. Aschenbrand SG, Angelosante AG, Kendall PC: Discriminant validity and clinical utility of the CBCL with anxiety-disordered youth. J Clin Child Adolesc Psychol; 2005 Dec;34(4):735-46
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Discriminant validity and clinical utility of the CBCL with anxiety-disordered youth.
  • This study investigated the utility of several scales of the Child Behavior Checklist (CBCL) when diagnosing anxiety disorders in youth.
  • Findings are discussed with regard to diagnosis of child anxiety and the clinical utility of the CBCL with anxious youth.

  • Genetic Alliance. consumer health - Anxiety.
  • MedlinePlus Health Information. consumer health - Anxiety.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16232070.001).
  • [ISSN] 1537-4416
  • [Journal-full-title] Journal of clinical child and adolescent psychology : the official journal for the Society of Clinical Child and Adolescent Psychology, American Psychological Association, Division 53
  • [ISO-abbreviation] J Clin Child Adolesc Psychol
  • [Language] eng
  • [Grant] United States / NIMH NIH HHS / MH / MH59087
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.; Validation Studies
  • [Publication-country] United States
  •  go-up   go-down


78. Lim ST, Levine AM: Non-AIDS-defining cancers and HIV infection. Curr HIV/AIDS Rep; 2005 Aug;2(3):146-53
MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-AIDS-defining cancers and HIV infection.
  • Apart from Kaposi's sarcoma, non-Hodgkin's lymphoma, and cervical cancer, which are considered as AIDS-defining, several additional cancers, referred to as non-AIDS-defining cancers, are also statistically increased in HIV-infected persons.
  • These include Hodgkin's disease, anal carcinoma, lung cancer, nonmelanomatous skin cancer, and testicular germ cell tumors, among others.
  • Although immunosuppression is consistently associated with an increased risk of AIDS-related malignancies, the role of immunosuppression in the pathogenesis of non-AIDS- defining cancers is controversial.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Acquir Immune Defic Syndr. 2003 Apr 15;32(5):527-33 [12679705.001]
  • [Cites] Sex Transm Dis. 2004 Feb;31(2):96-9 [14743072.001]
  • [Cites] Eur J Epidemiol. 1995 Dec;11(6):609-14 [8861842.001]
  • [Cites] Ann Thorac Surg. 2003 Feb;75(2):367-71 [12607641.001]
  • [Cites] J Acquir Immune Defic Syndr. 2000 Aug 15;24(5):444-50 [11035615.001]
  • [Cites] Hematol Oncol Clin North Am. 1991 Apr;5(2):343-56 [2022598.001]
  • [Cites] Lancet. 1998 Jun 20;351(9119):1833-9 [9652666.001]
  • [Cites] J Natl Cancer Inst. 1997 Nov 5;89(21):1602-8 [9362158.001]
  • [Cites] AIDS. 2003 Feb 14;17(3):371-5 [12556691.001]
  • [Cites] AIDS Care. 1996 Feb;8(1):5-14 [8664369.001]
  • [Cites] Ann Oncol. 1993 Sep;4(8):635-41 [8240994.001]
  • [Cites] J Clin Oncol. 1995 Oct;13(10):2540-6 [7595705.001]
  • [Cites] Eur J Cancer. 2001 Jul;37(10):1276-87 [11423259.001]
  • [Cites] AIDS. 1998 Mar 26;12(5):495-503 [9543448.001]
  • [Cites] J Infect Dis. 1998 Feb;177(2):361-7 [9466522.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):314-9 [9525431.001]
  • [Cites] JAMA. 1999 May 19;281(19):1822-9 [10340370.001]
  • [Cites] J Clin Oncol. 1995 Nov;13(11):2705-11 [7595728.001]
  • [Cites] Cancer. 2001 Dec 1;92(11):2739-45 [11753946.001]
  • [Cites] Int J STD AIDS. 2001 Feb;12(2):100-2 [11236097.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1823-30 [11078759.001]
  • [Cites] Blood. 2002 Sep 15;100(6):1984-8 [12200356.001]
  • [Cites] Am J Med. 1985 Feb;78(2):211-5 [3918441.001]
  • [Cites] AIDS. 1999 May 7;13(7):839-43 [10357384.001]
  • [Cites] AIDS. 2001 Nov 9;15(16):2157-64 [11684935.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):978-85 [15220706.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] N Engl J Med. 1998 Mar 26;338(13):853-60 [9516219.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3447-53 [12972519.001]
  • [Cites] Cancer. 1992 Jul 15;70(2):432-6 [1617592.001]
  • [Cites] Cancer. 1990 May 15;65(10):2248-54 [2346909.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]
  • [Cites] Ann Oncol. 1999 Feb;10(2):189-95 [10093688.001]
  • [Cites] Cancer. 2000 Feb 1;88(3):563-9 [10649248.001]
  • [Cites] Ann Oncol. 2003 Oct;14(10):1562-9 [14504059.001]
  • [Cites] AIDS. 2002 May 24;16(8):1155-61 [12004274.001]
  • [Cites] Ann Intern Med. 2003 Mar 18;138(6):453-9 [12639077.001]
  • [Cites] J Clin Oncol. 1995 Jun;13(6):1391-7 [7538557.001]
  • [Cites] J Clin Oncol. 2004 Apr 1;22(7):1348-9; author reply 1349-50 [15051794.001]
  • [Cites] Clin Infect Dis. 2003 Jul 15;37(2):292-8 [12856222.001]
  • [Cites] Am J Med. 2000 Jun 1;108(8):634-41 [10856411.001]
  • [Cites] Semin Oncol. 2000 Aug;27(4):480-8 [10950375.001]
  • [Cites] Hematol Oncol Clin North Am. 1996 Oct;10(5):997-1010 [8880192.001]
  • [Cites] Br J Cancer. 1998 Oct;78(7):966-70 [9764592.001]
  • [Cites] Chest. 1993 Feb;103(2):410-3 [8432128.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1985 Sep;11(9):1587-93 [3928544.001]
  • [Cites] Blood. 1999 Apr 1;93(7):2319-26 [10090942.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12667-71 [11058153.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1101-5 [9169819.001]
  • [Cites] Chest. 1998 Jan;113(1):154-61 [9440583.001]
  • [Cites] Mutat Res. 1999 Oct 19;429(2):249-59 [10526209.001]
  • [Cites] Eur J Cancer. 2000 Apr;36(6):754-8 [10762748.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10):1922-7 [12743144.001]
  • [Cites] Fundam Appl Toxicol. 1996 Aug;32(2):148-58 [8921318.001]
  • [Cites] Mutagenesis. 2000 Sep;15(5):405-10 [10970446.001]
  • [Cites] Int J Cancer. 2001 Dec 1;94(5):753-7 [11745473.001]
  • [Cites] J Acquir Immune Defic Syndr. 2001 Dec 15;28(5):422-8 [11744829.001]
  • [Cites] Ann Oncol. 1991 Feb;2 Suppl 2:201-5 [1710920.001]
  • [Cites] Lung Cancer. 2002 Apr;36(1):9-14 [11891027.001]
  • [Cites] Br J Cancer. 2003 Aug 4;89(3):457-9 [12888811.001]
  • [Cites] Am J Surg Pathol. 1996 Dec;20(12):1520-4 [8944046.001]
  • [Cites] Chest. 1992 Dec;102(6):1704-8 [1446476.001]
  • (PMID = 16091262.001).
  • [ISSN] 1548-3568
  • [Journal-full-title] Current HIV/AIDS reports
  • [ISO-abbreviation] Curr HIV/AIDS Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 64
  •  go-up   go-down


79. Schmidt E, Bröcker EB, Goebeler M: Rituximab in treatment-resistant autoimmune blistering skin disorders. Clin Rev Allergy Immunol; 2008 Feb;34(1):56-64
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab in treatment-resistant autoimmune blistering skin disorders.
  • It has been employed in more than 1 million patients with CD20-positive non-Hodgkin's lymphoma and severe side effects were only rarely observed.
  • Subsequently, the B cell-modulating effect of rituximab has encouraged its use in a variety of autoimmune diseases, including more than 40 patients with pemphigus.
  • In the majority of these patients, clinical remission was induced; however, serious adverse events were considerable higher compared to both patients with non-Hodgkin's lymphoma or nonbullous autoimmune disorders like lupus erythematosus, dermatomyositis, and rheumatoid arthritis.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Autoimmune Diseases / drug therapy. Immunologic Factors / therapeutic use. Skin Diseases, Vesiculobullous / classification

  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Dermatol. 2000 Feb;136(2):174-8 [10677092.001]
  • [Cites] Br J Dermatol. 2007 Aug;157(2):417-9 [17596155.001]
  • [Cites] Int Immunopharmacol. 2004 Aug;4(8):1117-24 [15222987.001]
  • [Cites] Br J Dermatol. 2007 Feb;156(2):352-6 [17223877.001]
  • [Cites] Bone Marrow Transplant. 2002 Sep;30(5):327-9 [12209356.001]
  • [Cites] Acta Derm Venereol. 2006;86(1):87-9 [16586007.001]
  • [Cites] Lancet. 2001 Nov 3;358(9292):1511-3 [11705566.001]
  • [Cites] Arch Dermatol. 2001 Mar;137(3):269-72 [11255323.001]
  • [Cites] Nat Rev Drug Discov. 2006 Jul;5(7):564-76 [16816838.001]
  • [Cites] N Engl J Med. 2006 Oct 26;355(17):1800-10 [17065642.001]
  • [Cites] Nat Rev Immunol. 2006 Oct;6(10):741-50 [16977339.001]
  • [Cites] N Engl J Med. 2004 Jun 17;350(25):2572-81 [15201414.001]
  • [Cites] Blood. 2006 Apr 1;107(7):2639-42 [16352811.001]
  • [Cites] Arthritis Rheum. 2004 Aug;50(8):2580-9 [15334472.001]
  • [Cites] J Rheumatol Suppl. 2006 May;77:24-8 [16652442.001]
  • [Cites] Br J Dermatol. 2003 Nov;149(5):926-37 [14632796.001]
  • [Cites] Br J Dermatol. 2005 Aug;153(2):449-51 [16086770.001]
  • [Cites] Pediatr Dermatol. 2005 Sep-Oct;22(5):461-4 [16191003.001]
  • [Cites] Br J Dermatol. 2005 Sep;153(3):620-5 [16120153.001]
  • [Cites] Br J Dermatol. 2003 Oct;149(4):899-901 [14616397.001]
  • [Cites] J Clin Invest. 2005 Apr;115(4):870-8 [15841176.001]
  • [Cites] Arch Dermatol. 2004 Jan;140(1):91-6 [14732665.001]
  • [Cites] Arthritis Rheum. 2004 Nov;50(11):3580-90 [15529346.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2006 Jan;20(1):69-74 [16405612.001]
  • [Cites] Ann Rheum Dis. 2002 Oct;61(10):883-8 [12228157.001]
  • [Cites] J Am Acad Dermatol. 2006 Jul;55(1):143-8 [16781310.001]
  • [Cites] Adv Dermatol. 2000;16:113-57; discussion 158 [11094626.001]
  • [Cites] Arch Dermatol. 2006 Feb;142(2):147-50 [16490841.001]
  • [Cites] N Engl J Med. 2006 Oct 26;355(17):1772-9 [17065638.001]
  • [Cites] Eur J Dermatol. 2006 May-Jun;16(3):266-70 [16709491.001]
  • [Cites] Blood. 2003 May 15;101(10):3857-61 [12531800.001]
  • [Cites] Arthritis Rheum. 2006 Nov;54(11):3612-22 [17075806.001]
  • [Cites] J Dtsch Dermatol Ges. 2004 Sep;2(9):774-91; quiz 792-3 [16279223.001]
  • [Cites] Clin Exp Immunol. 2005 Mar;139(3):439-46 [15730389.001]
  • [Cites] N Engl J Med. 1994 Nov 3;331(18):1207-11 [7935660.001]
  • [Cites] J Pediatr. 2006 May;148(5):623-627 [16737873.001]
  • [Cites] Arthritis Rheum. 2006 Feb;54(2):613-20 [16447239.001]
  • [Cites] Arthritis Rheum. 2005 Feb;52(2):601-7 [15692974.001]
  • [Cites] Arthritis Rheum. 2003 Feb;48(2):455-9 [12571855.001]
  • [Cites] Haematologica. 2003 Jul;88(7):811-23 [12857561.001]
  • [Cites] Clin Exp Dermatol. 2006 Jul;31(4):503-8 [16716150.001]
  • [Cites] Clin Exp Dermatol. 2006 Jan;31(1):143 [16309516.001]
  • [Cites] Rev Med Interne. 2007 Apr;28(4):266-8 [17188405.001]
  • (PMID = 18270859.001).
  • [ISSN] 1559-0267
  • [Journal-full-title] Clinical reviews in allergy & immunology
  • [ISO-abbreviation] Clin Rev Allergy Immunol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Autoantibodies; 0 / Glucocorticoids; 0 / Immunologic Factors; 0 / Immunosuppressive Agents; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 44
  •  go-up   go-down


80. Leung PW, Kwong SL, Tang CP, Ho TP, Hung SF, Lee CC, Hong SL, Chiu CM, Liu WS: Test-retest reliability and criterion validity of the Chinese version of CBCL, TRF, and YSR. J Child Psychol Psychiatry; 2006 Sep;47(9):970-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Test-retest reliability and criterion validity of the Chinese version of CBCL, TRF, and YSR.
  • BACKGROUND: Psychometric properties of the Chinese version of CBCL, TRF, and YSR were understudied.
  • The parents, teachers, and youths respectively completed the CBCL, TRF, and YSR.
  • RESULTS: The Chinese CBCL, TRF, and YSR were test-retest reliable and valid.
  • CBCL and TRF appeared to screen externalizing and ADHD problems better, while YSR screened internalizing problems better.
  • CONCLUSIONS: Clinicians should be cautious about score/case attenuation at retest while using CBCL, TRF, and YSR to chart patients' progress.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16930392.001).
  • [ISSN] 0021-9630
  • [Journal-full-title] Journal of child psychology and psychiatry, and allied disciplines
  • [ISO-abbreviation] J Child Psychol Psychiatry
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] England
  •  go-up   go-down


81. Biederman J, Monuteaux MC, Kendrick E, Klein KL, Faraone SV: The CBCL as a screen for psychiatric comorbidity in paediatric patients with ADHD. Arch Dis Child; 2005 Oct;90(10):1010-5
MedlinePlus Health Information. consumer health - Mood Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The CBCL as a screen for psychiatric comorbidity in paediatric patients with ADHD.
  • AIMS: To examine the informativeness of the Child Behavior Checklist (CBCL) as a screening tool to identify comorbid and non-comorbid cases of attention deficit hyperactivity disorder (ADHD) in a paediatrically referred population.
  • It was hypothesised that specific scales of the CBCL would help identify specific comorbidities within ADHD cases in the primary care setting.
  • A receiver operating curve (ROC) approach was used to determine which CBCL scales best differentiated between ADHD cases with and without its comorbidities with conduct, anxiety, and mood disorders.
  • RESULTS: ROC analysis showed that the CBCL Delinquent Behavior and Aggressive Behavior scales predicted the structured interview derived diagnoses of conduct and bipolar disorder, the Anxious/Depressed and Aggressive Behavior scales predicted major depression, and the Anxious/Depressed and Attention problems scales predicted anxiety disorders.
  • CONCLUSIONS: These results extend to a paediatrically referred population with previously reported findings in psychiatric samples documenting good convergence between structured interview diagnoses and syndrome congruent CBCL scales.
  • These findings support the utility of the CBCL as a screening tool for the identification of psychiatric comorbidity in ADHD youth in the primary care setting.

  • MedlinePlus Health Information. consumer health - Attention Deficit Hyperactivity Disorder.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Clin North Am. 1999 Oct;46(5):915-27, vii [10570696.001]
  • [Cites] Am J Psychiatry. 1991 May;148(5):564-77 [2018156.001]
  • [Cites] J Affect Disord. 1998 Nov;51(2):93-100 [10743842.001]
  • [Cites] J Consult Clin Psychol. 2001 Aug;69(4):683-98 [11550734.001]
  • [Cites] J Clin Child Psychol. 2001 Dec;30(4):492-502 [11708237.001]
  • [Cites] Am J Psychiatry. 2002 Jan;159(1):36-42 [11772687.001]
  • [Cites] Biol Psychiatry. 2003 Jun 1;53(11):1021-7 [12788247.001]
  • [Cites] Eur Child Adolesc Psychiatry. 2004;13 Suppl 1:I7-30 [15322953.001]
  • [Cites] Arch Gen Psychiatry. 1982 Oct;39(10):1157-67 [7125846.001]
  • [Cites] Arch Gen Psychiatry. 1984 Sep;41(9):845-52 [6466043.001]
  • [Cites] Arch Gen Psychiatry. 1987 Jan;44(1):69-76 [2432848.001]
  • [Cites] Psychol Bull. 1987 May;101(3):443-63 [3602250.001]
  • [Cites] J Abnorm Child Psychol. 1988 Apr;16(2):219-31 [3385085.001]
  • [Cites] JAMA. 1988 Oct 21;260(15):2256-8 [2902237.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 1989 Sep;28(5):707-13 [2793798.001]
  • [Cites] J Clin Psychiatry. 1990 May;51 Suppl:20-6; discussion 50-3 [1970814.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 1992 May;31(3):449-54 [1592776.001]
  • [Cites] J Abnorm Child Psychol. 1993 Jun;21(3):287-313 [8335765.001]
  • [Cites] J Child Psychol Psychiatry. 1993 Oct;34(7):1241-51 [8245144.001]
  • [Cites] J Consult Clin Psychol. 1994 Oct;62(5):1017-25 [7806710.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 1995 Apr;34(4):464-71 [7751260.001]
  • [Cites] Arch Gen Psychiatry. 1996 May;53(5):437-46 [8624187.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 1996 Jun;35(6):734-42 [8682754.001]
  • [Cites] J Paediatr Child Health. 1996 Oct;32(5):405-11 [8933400.001]
  • [Cites] J Child Psychol Psychiatry. 1997 Sep;38(6):625-32 [9315972.001]
  • [Cites] JAMA. 1998 Apr 8;279(14):1100-7 [9546570.001]
  • [Cites] J Paediatr Child Health. 1999 Apr;35(2):199-203 [10365361.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 1999 Aug;38(8):966-75 [10434488.001]
  • [Cites] Eur Child Adolesc Psychiatry. 1999 Dec;8(4):247-54 [10654117.001]
  • (PMID = 16177156.001).
  • [ISSN] 1468-2044
  • [Journal-full-title] Archives of disease in childhood
  • [ISO-abbreviation] Arch. Dis. Child.
  • [Language] ENG
  • [Grant] United States / NIMH NIH HHS / MH / R01MH-41314
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1720123
  •  go-up   go-down


82. Biederman J, Ball SW, Monuteaux MC, Kaiser R, Faraone SV: CBCL clinical scales discriminate ADHD youth with structured-interview derived diagnosis of oppositional defiant disorder (ODD). J Atten Disord; 2008 Jul;12(1):76-82
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CBCL clinical scales discriminate ADHD youth with structured-interview derived diagnosis of oppositional defiant disorder (ODD).
  • OBJECTIVE: To evaluate the association between the clinical scales of the child behavior checklist (CBCL) and the comorbid diagnosis of oppositional defiant disorder (ODD) in a large sample of youth with attention deficit hyperactivity disorder (ADHD).
  • Conditional probability analysis was used to examine the correspondence between CBCL Clinical Scales with the structured-interview derived diagnosis of ODD.
  • RESULTS: Conditional probability analysis showed that the CBCL Aggression Scale best predicted a structured-interview derived diagnosis of ODD in boys and girls with ADHD.
  • CONCLUSION: These findings suggest that the CBCL Aggression Scale could serve as a rapid and cost-effective screening instrument to help identify cases likely to meet clinical criteria for ODD in the context of ADHD

  • Genetic Alliance. consumer health - Oppositional defiant disorder.
  • MedlinePlus Health Information. consumer health - Attention Deficit Hyperactivity Disorder.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17494835.001).
  • [ISSN] 1087-0547
  • [Journal-full-title] Journal of attention disorders
  • [ISO-abbreviation] J Atten Disord
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / R01 HD036317; United States / NIMH NIH HHS / MH / R01 MH050657
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


83. Brasil HH, Bordin IA: Convergent validity of K-SADS-PL by comparison with CBCL in a Portuguese speaking outpatient population. BMC Psychiatry; 2010;10:83
MedlinePlus Health Information. consumer health - Child Behavior Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Convergent validity of K-SADS-PL by comparison with CBCL in a Portuguese speaking outpatient population.
  • The present study aims to examine the convergent validity of the Brazilian version of the Schedule for Affective Disorders and Schizophrenia for School-Age Children/Present and Lifetime Version (K-SADS-PL) by comparison with the Child Behavior Checklist (CBCL), a parental screening measure for child/adolescent emotional/behavior problems.
  • METHODS: An experienced child psychiatrist blind to CBCL results applied the K-SADS-PL to a consecutive sample of 78 children (6-14 years) referred to a public child mental health outpatient clinic (response rate = 75%).
  • All subjects obtained T-scores on CBCL scales (internalizing, externalizing, total problems).
  • RESULTS: Significant differences in CBCL mean T-scores were observed between disordered and non-disordered children.
  • CONCLUSIONS: Evidence of convergent validity was found when comparing K-SADS-PL results with CBCL data.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Child Adolesc Psychiatr Clin N Am. 2001 Oct;10(4):763-76, ix [11588802.001]
  • [Cites] BMC Psychiatry. 2006;6:10 [16539703.001]
  • [Cites] Yonsei Med J. 2004 Feb 29;45(1):81-9 [15004873.001]
  • [Cites] Encephale. 2004 Mar-Apr;30(2):122-34 [15107714.001]
  • [Cites] Compr Psychiatry. 1982 Jan-Feb;23(1):75-84 [7056044.001]
  • [Cites] J Am Acad Child Psychiatry. 1982 Sep;21(5):468-73 [7130556.001]
  • [Cites] J Abnorm Child Psychol. 1985 Dec;13(4):579-95 [4078188.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 1987 Sep;26(5):621-30 [3312159.001]
  • [Cites] J Abnorm Child Psychol. 1988 Apr;16(2):219-31 [3385085.001]
  • [Cites] J Abnorm Child Psychol. 1990 Aug;18(4):393-406 [2246431.001]
  • [Cites] Br J Psychiatry. 1991 Jun;158:743-51 [1873626.001]
  • [Cites] J Child Psychol Psychiatry. 1993 Feb;34(2):189-213 [8444992.001]
  • [Cites] J Abnorm Child Psychol. 1993 Jun;21(3):287-313 [8335765.001]
  • [Cites] J Child Psychol Psychiatry. 1996 Jan;37(1):35-49 [8655657.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 1997 Jul;36(7):980-8 [9204677.001]
  • [Cites] J Child Psychol Psychiatry. 1997 Sep;38(6):625-32 [9315972.001]
  • [Cites] Isr J Psychiatry Relat Sci. 1997;34(3):179-86 [9334522.001]
  • [Cites] Brain Inj. 2004 Apr;18(4):377-90 [14742151.001]
  • (PMID = 20955616.001).
  • [ISSN] 1471-244X
  • [Journal-full-title] BMC psychiatry
  • [ISO-abbreviation] BMC Psychiatry
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2984471
  •  go-up   go-down


84. Chattopadhyay A, Slater DN, Hancock BW: Cutaneous CD56 positive natural killer and cytotoxic T-cell lymphomas. Int J Oncol; 2005 Jun;26(6):1559-62
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous CD56 positive natural killer and cytotoxic T-cell lymphomas.
  • We report two cases of CD56 positive natural killer (NK) cell and cytotoxic T-cell cutaneous lymphomas and review the literature on these rare forms of non-Hodgkin's lymphoma.
  • The first case was diagnosed to have extra nodal NK/T-cell lymphoma, nasal-type.
  • The second case was diagnosed as subcutaneous panniculitis-like T-cell lymphoma, CD56 positive variant.
  • She presented with skin nodules that were quiescent for 10 years.
  • She died within 15 months of her lymphoma changing to its aggressive form.
  • These cases illustrate the often poor prognosis of cutaneous CD56 positive lymphomas.
  • [MeSH-major] Antigens, CD56 / analysis. Killer Cells, Natural / immunology. Lymphoma, T-Cell, Cutaneous / immunology. Skin Neoplasms / immunology. T-Lymphocytes, Cytotoxic / immunology

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15870869.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, CD56; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


85. Theander E, Henriksson G, Ljungberg O, Mandl T, Manthorpe R, Jacobsson LT: Lymphoma and other malignancies in primary Sjögren's syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis; 2006 Jun;65(6):796-803
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoma and other malignancies in primary Sjögren's syndrome: a cohort study on cancer incidence and lymphoma predictors.
  • OBJECTIVES: To assess the risk of lymphoproliferative disease or other malignancy (standardised incidence ratios (SIRs)), in patients with primary Sjögren's syndrome according to the American-European Consensus Criteria (AECC), compared with patients with sicca syndrome (non-AECC) and the background population.
  • To identify predictors of malignancy and describe lymphoma types and survival probabilities.
  • METHODS: A linked register study using information from the Malmö Primary SS Register, Swedish Cancer Register, and Cause-of-Death Register for calculation of SIRs was carried out.
  • SIRs (95% confidence interval (CI)) for malignancies in total and for non-Hodgkin's lymphomas (NHL) were 1.42 (0.98 to 2.00) and 15.57 (7.77 to 27.85), respectively, in those fulfilling the AECC (n = 286).
  • In non-AECC sicca patients (n = 221) SIR for malignancy of any kind was 0.77 (0.41 to 1.32); no lymphoproliferative neoplasms were detected.
  • Significant predictors of lymphoproliferative disease were purpura/skin vasculitis (hazard ratio (HR) = 4.64, 95% CI 1.13 to 16.45), low complement factor C3 (HR = 6.18, 95% CI 1.57 to 24.22), low C4 (HR = 9.49, 95% CI 1.94 to 46.54), CD4+ T lymphocytopenia (HR = 8.14, 95% CI 2.10 to 31.53), and a low CD4+/CD8+ T cell ratio < or = 0.8 (HR = 10.92, 95% CI 2.80 to 41.83).
  • 7/12 (58%) NHLs were diffuse large B cell lymphomas.
  • CD4+ T lymphocytopenia is an additional strong risk factor for developing lymphoma.
  • [MeSH-major] Lymphoma / complications. Sjogren's Syndrome / complications


86. Spatola CA, Rende R, Battaglia M: Genetic and environmental influences upon the CBCL/6-18 DSM-oriented scales: similarities and differences across three different computational approaches and two age ranges. Eur Child Adolesc Psychiatry; 2010 Aug;19(8):647-58
MedlinePlus Health Information. consumer health - Child Behavior Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic and environmental influences upon the CBCL/6-18 DSM-oriented scales: similarities and differences across three different computational approaches and two age ranges.
  • Inasmuch as the newly established DSM-oriented CBCL/6-18 scales are to be increasingly employed to assess clinical/high-risk populations, it becomes important to explore their aetiology both within the normal- and the extreme range of variation in general population samples and to compare the results obtained in different age groups.
  • We investigated by the Quantitative Maximum Likelihood, the De Fries-Fulker, and the Ordinal Maximum Likelihood methods the genetic and environmental influences upon the five DSM-oriented CBCL/6-18 scales in 796 twins aged 8-17 years belonging to the general population-based Italian Twin Registry.
  • When children were analysed together regardless of age, most best-fitting solutions yielded genetic and non-shared environmental factors as the sole influences for DSM-oriented CBCL/6-18 behaviours, both for the normal and the extreme variations.
  • Oppositional-Defiant, Attention Deficit/Hyperactivity, and Conduct Problems appeared-with few exceptions-influenced only by genetic and non-shared environmental factors in both age groups, according to all three computational approaches.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Child Psychol Psychiatry. 1999 Sep;40(6):953-8 [10509889.001]
  • [Cites] J Child Psychol Psychiatry. 1998 Jul;39(5):687-97 [9690932.001]
  • [Cites] J Child Psychol Psychiatry. 1993 Nov;34(8):1387-98 [8294525.001]
  • [Cites] J Child Psychol Psychiatry. 1987 May;28(3):437-53 [3597566.001]
  • [Cites] Behav Genet. 2003 Sep;33(5):591-605 [14574135.001]
  • [Cites] Bipolar Disord. 2005 Dec;7(6):518-24 [16403177.001]
  • [Cites] Biol Psychol. 2002 Oct;61(1-2):33-51 [12385668.001]
  • [Cites] J Anxiety Disord. 2008;22(1):126-34 [17321103.001]
  • [Cites] Behav Genet. 1994 Mar;24(2):149-53 [8024531.001]
  • [Cites] J Child Psychol Psychiatry. 2009 Jan;50(1-2):126-32 [19076263.001]
  • [Cites] J Child Psychol Psychiatry. 1997 Oct;38(7):861-5 [9363585.001]
  • [Cites] Behav Genet. 1989 Jan;19(1):9-35 [2712816.001]
  • [Cites] J Clin Child Adolesc Psychol. 2003 Sep;32(3):328-40 [12881022.001]
  • [Cites] J Child Psychol Psychiatry. 2004 Mar;45(3):577-88 [15055376.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 2000 Feb;39(2):232-9 [10673835.001]
  • [Cites] Twin Res. 2004 Dec;7(6):659-69 [15607017.001]
  • [Cites] J Abnorm Child Psychol. 1995 Dec;23(6):661-84 [8609307.001]
  • [Cites] J Consult Clin Psychol. 2001 Aug;69(4):703-5 [11550736.001]
  • [Cites] J Clin Child Adolesc Psychol. 2006 Jun;35(2):237-43 [16597219.001]
  • [Cites] Eur Child Adolesc Psychiatry. 2009 Mar;18(3):136-43 [19129966.001]
  • [Cites] J Consult Clin Psychol. 1994 Jun;62(3):510-21 [8063977.001]
  • [Cites] Twin Res. 2002 Oct;5(5):382-6 [12537863.001]
  • [Cites] J Child Psychol Psychiatry. 2009 Mar;50(3):317-25 [19175813.001]
  • [Cites] J Child Psychol Psychiatry. 2008 Dec;49(12):1257-69 [18355216.001]
  • [Cites] Behav Genet. 2008 Jan;38(1):11-23 [18074222.001]
  • [Cites] J Anxiety Disord. 2006;20(6):760-77 [16326068.001]
  • [Cites] Br J Psychiatry. 1994 Aug;165(2):259-65 [7953041.001]
  • [Cites] Arch Gen Psychiatry. 2009 Jan;66(1):64-71 [19124689.001]
  • [Cites] Am J Psychiatry. 2005 Sep;162(9):1614-20 [16135619.001]
  • [Cites] Behav Genet. 2003 May;33(3):271-8 [12837017.001]
  • [Cites] Biol Psychiatry. 2005 Oct 1;58(7):562-8 [16239161.001]
  • [Cites] Ann Hum Genet. 1972 Nov;36(2):163-84 [4676360.001]
  • [Cites] Twin Res. 1998 May;1(1):25-33 [10051354.001]
  • [Cites] Eur Child Adolesc Psychiatry. 2008 Mar;17(2):82-92 [17846816.001]
  • [Cites] Behav Genet. 2001 Mar;31(2):179-91 [11545535.001]
  • [Cites] Behav Genet. 2004 May;34(3):229-42 [14990864.001]
  • [Cites] J Child Psychol Psychiatry. 1997 Jul;38(5):515-25 [9255695.001]
  • [Cites] J Child Psychol Psychiatry. 2002 Jan;43(1):65-79 [11848337.001]
  • [Cites] Behav Genet. 1996 Jul;26(4):419-26 [8771902.001]
  • [Cites] Behav Genet. 2003 Sep;33(5):575-89 [14574134.001]
  • [Cites] Behav Genet. 1991 May;21(3):257-69 [1863259.001]
  • [Cites] J Clin Child Adolesc Psychol. 2006 Feb;35(1):127-35 [16390308.001]
  • [Cites] Behav Genet. 1985 Sep;15(5):467-73 [4074272.001]
  • [Cites] J Child Psychol Psychiatry. 2003 Feb;44(2):180-92 [12587855.001]
  • [Cites] Eur Child Adolesc Psychiatry. 1999 Dec;8(4):247-54 [10654117.001]
  • [Cites] Genes Brain Behav. 2005 Nov;4(8):466-81 [16268991.001]
  • [Cites] Behav Genet. 1992 Jul;22(4):489-97 [1503550.001]
  • [Cites] J Fam Psychol. 2005 Dec;19(4):611-8 [16402876.001]
  • [Cites] Am J Psychiatry. 1999 Apr;156(4):569-74 [10200736.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 2007 May;46(5):619-27 [17450053.001]
  • [Cites] Biol Psychiatry. 2006 Nov 1;60(9):912-20 [16735031.001]
  • [Cites] J Clin Child Adolesc Psychol. 2002 Dec;31(4):505-12 [12402569.001]
  • (PMID = 20336335.001).
  • [ISSN] 1435-165X
  • [Journal-full-title] European child & adolescent psychiatry
  • [ISO-abbreviation] Eur Child Adolesc Psychiatry
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Twin Study
  • [Publication-country] Germany
  •  go-up   go-down


87. Derks EM, Hudziak JJ, Dolan CV, Ferdinand RF, Boomsma DI: The relations between DISC-IV DSM diagnoses of ADHD and multi-informant CBCL-AP syndrome scores. Compr Psychiatry; 2006 Mar-Apr;47(2):116-22
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The relations between DISC-IV DSM diagnoses of ADHD and multi-informant CBCL-AP syndrome scores.
  • BACKGROUND: Previous studies have examined the relation between attention problems (APs) obtained with the Child Behavior Checklist (CBCL) and attention deficit hyperactivity disorder (ADHD) assessed with the Diagnostic and Statistical Manual of Mental Disorders (DSM).
  • The mothers of a sample of 283 boys and 291 girls who scored either low or high on longitudinal maternal CBCL-AP were interviewed.

  • MedlinePlus Health Information. consumer health - Attention Deficit Hyperactivity Disorder.
  • MedlinePlus Health Information. consumer health - Child Behavior Disorders.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16490569.001).
  • [ISSN] 0010-440X
  • [Journal-full-title] Comprehensive psychiatry
  • [ISO-abbreviation] Compr Psychiatry
  • [Language] eng
  • [Grant] United States / NIMH NIH HHS / MH / MH58799
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


88. Syed EU, Hussein SA, Azam SI, Khan AG: Comparison of Urdu version of Strengths and Difficulties Questionnaire (SDQ) and the Child Behaviour Check List (CBCL) amongst primary school children in Karachi. J Coll Physicians Surg Pak; 2009 Jun;19(6):375-9
MedlinePlus Health Information. consumer health - Mental Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of Urdu version of Strengths and Difficulties Questionnaire (SDQ) and the Child Behaviour Check List (CBCL) amongst primary school children in Karachi.
  • OBJECTIVE: To compare CBCL (Child Behaviour Check Llist) Urdu, with the validated Urdu version of Strengths and Difficulties Questionnaire (SDQ) used as "gold standard" among school children in Karachi, Pakistan, and to develop local cutoffs for CBCL using SDQ as a gold standard.
  • METHODOLOGY: The Strengths and Difficulties Questionnaire (SDQ) and Child Behaviour Check List (CBCL) was completed by parents of 5-11 years old primary school children in Karachi.
  • Appropriate cutoff points for total problem, internalizing and externalizing scales were obtained for CBCL.
  • RESULTS: A total of 556 parents filled out both the SDQ Urdu version as well as CBCL.
  • Scores from the parent rated total SDQ scores were highly correlated with the total CBCL scores (r=0.589).
  • The local cutoffs derived for CBCL were considerably lower than USA norms.
  • Slightly higher cutoff for males was found as compared to females for the total CBCL scores.
  • CONCLUSION: Like the original English version, the Urdu version of CBCL and SDQ are both equally valid assessment tools to be used for both clinical and research purpose in Pakistani settings, where Urdu is widely spoken and understood.

  • MedlinePlus Health Information. consumer health - Child Mental Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19486578.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Validation Studies
  • [Publication-country] Pakistan
  •  go-up   go-down


89. Spatola CA, Fagnani C, Pesenti-Gritti P, Ogliari A, Stazi MA, Battaglia M: A general population twin study of the CBCL/6-18 DSM-oriented scales. J Am Acad Child Adolesc Psychiatry; 2007 May;46(5):619-27
MedlinePlus Health Information. consumer health - Attention Deficit Hyperactivity Disorder.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A general population twin study of the CBCL/6-18 DSM-oriented scales.
  • OBJECTIVE: To explore the contributions of genetic and environmental influences to individual variation and covariation of the Child Behavior Checklist (CBCL) DSM-oriented scales (DOS) originally proposed by Achenbach and associates in 2001.
  • METHOD: A classic twin study of 398 twin pairs ages 8 to 17 years belonging to the population-based Italian Twin Registry, assessed by parents using the CBCL for Ages 6 to 18 (CBCL/6-18).
  • RESULTS: Univariate analyses showed that compared with the classic CBCL/6-18 empirical subscales, the DOS have higher heritability (lowest 0.54 for Anxiety Problems, highest 0.71 for Conduct Problems) and simpler causal structure in that the phenotypic variance was satisfactorily explained by additive genetic and unique environmental factors only.
  • Multivariate analyses showed that the causes of phenotypic correlation among the different DOS can be attributed to one common genetic factor and to two idiosyncratic environmental factors, each loading differently on the Internalizing (Anxiety and Affective Problems) and the Externalizing (Attention-Deficit/Hyperactivity, Oppositional Defiant, and Conduct Problems) CBCL/6-18 DOS.
  • CONCLUSIONS: Several common risk factors of both genetic and environmental nature can simultaneously affect a child's proneness to develop the psychopathological signs and symptoms captured by the CBCL/6-18 DOS.

  • MedlinePlus Health Information. consumer health - Anxiety.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17450053.001).
  • [ISSN] 0890-8567
  • [Journal-full-title] Journal of the American Academy of Child and Adolescent Psychiatry
  • [ISO-abbreviation] J Am Acad Child Adolesc Psychiatry
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Twin Study
  • [Publication-country] United States
  •  go-up   go-down


90. Diler RS, Birmaher B, Axelson D, Goldstein B, Gill M, Strober M, Kolko DJ, Goldstein TR, Hunt J, Yang M, Ryan ND, Iyengar S, Dahl RE, Dorn LD, Keller MB: The Child Behavior Checklist (CBCL) and the CBCL-bipolar phenotype are not useful in diagnosing pediatric bipolar disorder. J Child Adolesc Psychopharmacol; 2009 Feb;19(1):23-30
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Child Behavior Checklist (CBCL) and the CBCL-bipolar phenotype are not useful in diagnosing pediatric bipolar disorder.
  • OBJECTIVES: Previous studies have suggested that the sum of Attention, Aggression, and Anxious/Depressed subscales of Child Behavior Checklist (CBCL-PBD; pediatric bipolar disorder phenotype) may be specific to pediatric bipolar disorder (BP).
  • The purpose of this study was to evaluate the usefulness of the CBCL and CBCL-PBD to identify BP in children <12 years old.
  • The CBCL T-scores and area under the curve (AUC) scores were calculated and compared among the above-noted groups.
  • RESULTS: Forty one percent of BP children did not have significantly elevated CBCL-PBD scores (>or=2 standard deviations [SD]).
  • The sensitivity and specificity of CBCL-PBD >or= 2 SD for diagnosis of BP was 57% and 70-77%, respectively, and the accuracy of CBCL-PBD for identifying a BP diagnosis was moderate (AUC = 0.72-0.78).
  • CONCLUSION: The CBCL and the CBCL-PBD showed that BP children have more severe psychopathology than HC and children with other psychopathology, but they were not useful as a proxy for Diagnostic and Statistical Manual of Mental Disorders, 4(th) edition (DSM-IV) diagnosis of BP.

  • Genetic Alliance. consumer health - Bipolar Disorder.
  • MedlinePlus Health Information. consumer health - Bipolar Disorder.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bipolar Disord. 2007 May;9(3):243-51 [17430299.001]
  • [Cites] Circulation. 2007 Feb 6;115(5):654-7 [17283280.001]
  • [Cites] Bipolar Disord. 2007 Dec;9(8):895-900 [18076540.001]
  • [Cites] Bipolar Disord. 2008 Jun;10(4):546-53 [18452451.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 1996 Jun;35(6):734-42 [8682754.001]
  • [Cites] J Affect Disord. 1998 Nov;51(2):93-100 [10743842.001]
  • [Cites] J Affect Disord. 1998 Nov;51(2):113-21 [10743844.001]
  • [Cites] J Affect Disord. 1998 Nov;51(2):123-35 [10743845.001]
  • [Cites] Arch Gen Psychiatry. 2000 Sep;57(9):867-72 [10986550.001]
  • [Cites] J Psychiatr Res. 2002 Sep-Oct;36(5):337-45 [12127602.001]
  • [Cites] Biol Psychiatry. 2003 Jun 1;53(11):1021-7 [12788247.001]
  • [Cites] J Child Adolesc Psychopharmacol. 2003 Winter;13(4):471-88 [14977460.001]
  • [Cites] Korean J Radiol. 2004 Jan-Mar;5(1):11-8 [15064554.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 2004 Jul;43(7):847-58 [15213586.001]
  • [Cites] Arch Gen Psychiatry. 1983 Nov;40(11):1228-31 [6639293.001]
  • [Cites] Science. 1988 Jun 3;240(4857):1285-93 [3287615.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 1995 Apr;34(4):464-71 [7751260.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 1997 Jul;36(7):980-8 [9204677.001]
  • [Cites] J Paediatr Child Health. 1999 Apr;35(2):199-203 [10365361.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 2005 Aug;44(8):823-8 [16034285.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 2005 Sep;44(9):846-71 [16113615.001]
  • [Cites] Arch Dis Child. 2005 Oct;90(10):1010-5 [16177156.001]
  • [Cites] Biol Psychiatry. 2005 Oct 1;58(7):569-75 [15950197.001]
  • [Cites] Biol Psychiatry. 2005 Oct 1;58(7):562-8 [16239161.001]
  • [Cites] Bipolar Disord. 2005 Dec;7(6):518-24 [16403177.001]
  • [Cites] Arch Gen Psychiatry. 2006 Feb;63(2):175-83 [16461861.001]
  • [Cites] Arch Gen Psychiatry. 2006 Oct;63(10):1139-48 [17015816.001]
  • [Cites] Biol Psychiatry. 2007 Jul 15;62(2):115-20 [16950211.001]
  • (PMID = 19232020.001).
  • [ISSN] 1557-8992
  • [Journal-full-title] Journal of child and adolescent psychopharmacology
  • [ISO-abbreviation] J Child Adolesc Psychopharmacol
  • [Language] ENG
  • [Grant] United States / NIMH NIH HHS / MH / R01 MH059691; United States / NIMH NIH HHS / MH / P01 MH041712-110004; United States / NIMH NIH HHS / MH / R01 MH057727-06A1; United States / NIMH NIH HHS / MH / R01 MH059929; United States / NIMH NIH HHS / MH / MH059929-06A2; United States / NIMH NIH HHS / MH / P01 MH041712; United States / NIMH NIH HHS / MH / MH057727-06A1; United States / NIMH NIH HHS / MH / R01 MH057727; United States / NIMH NIH HHS / MH / MH041712-110004; United States / NIMH NIH HHS / MH / R01 MH059929-06A2
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS108895; NLM/ PMC2753490
  •  go-up   go-down


91. Krol NP, De Bruyn EE, Coolen JC, van Aarle EJ: From CBCL to DSM: a comparison of two methods to screen for DSM-IV diagnoses using CBCL data. J Clin Child Adolesc Psychol; 2006 Feb;35(1):127-35
MedlinePlus Health Information. consumer health - Mental Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] From CBCL to DSM: a comparison of two methods to screen for DSM-IV diagnoses using CBCL data.
  • The screening efficiency of 2 methods to convert Child Behavior Checklist (CBCL) assessment data into Diagnostic and Statistical Manual of Mental Disorders (4th ed.
  • The Machine-Aided Diagnosis (MAD) method converts CBCL input data directly into DSM-IV symptom criteria.
  • DISC-IV interviews and CBCL reports from parents of 44 children, 25 boys, and 19 girls, ages 6 to 17 were used.

  • MedlinePlus Health Information. consumer health - Child Mental Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16390308.001).
  • [ISSN] 1537-4416
  • [Journal-full-title] Journal of clinical child and adolescent psychology : the official journal for the Society of Clinical Child and Adolescent Psychology, American Psychological Association, Division 53
  • [ISO-abbreviation] J Clin Child Adolesc Psychol
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] United States
  •  go-up   go-down


92. Galli F, D'Antuono G, Tarantino S, Viviano F, Borrelli O, Chirumbolo A, Cucchiara S, Guidetti V: Headache and recurrent abdominal pain: a controlled study by the means of the Child Behaviour Checklist (CBCL). Cephalalgia; 2007 Mar;27(3):211-9
MedlinePlus Health Information. consumer health - Mental Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Headache and recurrent abdominal pain: a controlled study by the means of the Child Behaviour Checklist (CBCL).
  • The psychological profile had been made according to the Child Behaviour Checklist 4-18 (CBCL).
  • anova one-way analysis was used to compare CBCL scales and subscales between groups.
  • Headache and RAP showed a very similar trend vs. control for the main scales of the CBCL, with a statistically significant tendency to show problems in the Internalizing scale (anxiety, mood and somatic complaints) and no problems in the Externalizing (behavioural) scale.

  • MedlinePlus Health Information. consumer health - Abdominal Pain.
  • MedlinePlus Health Information. consumer health - Child Mental Health.
  • MedlinePlus Health Information. consumer health - Headache.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cephalalgia. 2008 May;28(5):571-2; author reply 572 [18399821.001]
  • (PMID = 17381555.001).
  • [ISSN] 0333-1024
  • [Journal-full-title] Cephalalgia : an international journal of headache
  • [ISO-abbreviation] Cephalalgia
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article
  • [Publication-country] England
  •  go-up   go-down


93. Ayer L, Althoff R, Ivanova M, Rettew D, Waxler E, Sulman J, Hudziak J: Child Behavior Checklist Juvenile Bipolar Disorder (CBCL-JBD) and CBCL Posttraumatic Stress Problems (CBCL-PTSP) scales are measures of a single dysregulatory syndrome. J Child Psychol Psychiatry; 2009 Oct;50(10):1291-300
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Child Behavior Checklist Juvenile Bipolar Disorder (CBCL-JBD) and CBCL Posttraumatic Stress Problems (CBCL-PTSP) scales are measures of a single dysregulatory syndrome.
  • BACKGROUND: The Child Behavior Checklist Juvenile Bipolar Disorder (CBCL-JBD) profile and Posttraumatic Stress Problems (CBCL-PTSP) scale have been used to assess juvenile bipolar disorder (JBD) and posttraumatic stress disorder (PTSD), respectively.
  • We aimed to describe and identify the overlap between the CBCL-JBD profile and CBCL-PTSP scales.
  • METHOD: Two thousand and twenty-nine (2029) children from a nationally representative sample (1073 boys, 956 girls; mean age = 11.98; age range = 6-18) were rated on emotional and behavior problems by their parents using the CBCL.
  • Comparative model testing via structural equation modeling was conducted to determine whether the CBCL-JBD profile and CBCL-PTSP scale are best described as measuring separate versus unitary constructs.
  • RESULTS: The CBCL-JBD and CBCL-PTSP demonstrated a high degree of overlap (r = .89) at the latent variable level.
  • The best fitting, most parsimonious model was one in which the CBCL-JBD and CBCL-PTSP items identified a single latent construct, which was associated with higher parental endorsement of child suicidal behavior, and lower functioning.
  • CONCLUSIONS: The CBCL-JBD profile and CBCL-PTSP scale overlap to a remarkable degree, and may be best described as measures of a single syndrome.
  • These results contribute to the ongoing debate about the utility of the CBCL-JBD and CBCL-PTSP profiles, and offer promising methods of empirically based measurement of disordered self-regulation in youth.

  • Genetic Alliance. consumer health - CHILD Syndrome.
  • Genetic Alliance. consumer health - Bipolar Disorder.
  • MedlinePlus Health Information. consumer health - Bipolar Disorder.
  • MedlinePlus Health Information. consumer health - Post-Traumatic Stress Disorder.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19486226.001).
  • [ISSN] 1469-7610
  • [Journal-full-title] Journal of child psychology and psychiatry, and allied disciplines
  • [ISO-abbreviation] J Child Psychol Psychiatry
  • [Language] eng
  • [Grant] United States / NIMH NIH HHS / MH / K08 MH069562
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


94. Althoff RR, Verhulst FC, Rettew DC, Hudziak JJ, van der Ende J: Adult outcomes of childhood dysregulation: a 14-year follow-up study. J Am Acad Child Adolesc Psychiatry; 2010 Nov;49(11):1105-16
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Using a general population sample, the adult outcomes of children who presented with severe problems with self-regulation defined as being concurrently rated highly on attention problems, aggressive behavior, and anxious-depression on the Child Behavior Checklist-Dysregulation Profile (CBCL-DP) were examined.
  • CBCLs were completed by parents at baseline when children from the different cohorts were 4 to 16 years of age and sampled every 2 years for the next 14 years.
  • At year 14 the CBCL and DSM interview data were collected.
  • Logistic regression was used to compare and contrast outcomes for children with and without dysregulation, as measured by the latent-class-defined CBCL-DP.
  • RESULTS: Presence of childhood CBCL-DP at wave 1 was associated with increased rates of adult anxiety disorders, mood disorders, disruptive behavior disorders, and drug abuse 14 years later.
  • After controlling for co-occurring disorders in adulthood, associations with anxiety and disruptive behavior disorders with the CBCL-DP remained, whereas the others were not significant.
  • CONCLUSIONS: A child reported to be in the CBCL-DP class is at increased risk for problems with regulating affect, behavior, and cognition in adulthood.

  • MedlinePlus Health Information. consumer health - Child Behavior Disorders.
  • MedlinePlus Health Information. consumer health - Drug Abuse.
  • MedlinePlus Health Information. consumer health - Drugs and Young People.
  • MedlinePlus Health Information. consumer health - Mood Disorders.
  • MedlinePlus Health Information. consumer health - Opioid Abuse and Addiction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American Academy of Child and Adolescent Psychiatry. Published by Elsevier Inc. All rights reserved.
  • [Cites] Child Adolesc Psychiatr Clin N Am. 2000 Jul;9(3):711-26 [10944664.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 2001 Jun;40(6):673-7 [11392345.001]
  • [Cites] Br J Psychiatry. 2001 Sep;179:203-9 [11532796.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 2001 Sep;40(9):1094-102 [11556634.001]
  • [Cites] Child Adolesc Psychiatr Clin N Am. 2002 Jul;11(3):499-518 [12222080.001]
  • [Cites] Am J Psychiatry. 2003 Mar;160(3):430-7 [12611821.001]
  • [Cites] Biol Psychiatry. 2003 Jun 1;53(11):1021-7 [12788247.001]
  • [Cites] J Child Adolesc Psychopharmacol. 2003 Summer;13(2):123-36 [12880507.001]
  • [Cites] Child Dev. 2004 Mar-Apr;75(2):334-9 [15056187.001]
  • [Cites] JAMA. 1983 Apr 1;249(13):1743-5 [6827763.001]
  • [Cites] Acta Psychiatr Scand Suppl. 1985;323:1-108 [3879096.001]
  • [Cites] J Child Psychol Psychiatry. 1991 Nov;32(7):1063-80 [1787137.001]
  • [Cites] Eur Child Adolesc Psychiatry. 1996;5 Suppl 1:44-6 [9010663.001]
  • [Cites] Addiction. 1997 Oct;92(10):1289-304 [9489046.001]
  • [Cites] Soc Psychiatry Psychiatr Epidemiol. 1998 Feb;33(2):80-8 [9503991.001]
  • [Cites] Biol Psychiatry. 2005 Oct 1;58(7):562-8 [16239161.001]
  • [Cites] J Abnorm Psychol. 2005 Nov;114(4):505-21 [16351374.001]
  • [Cites] Bipolar Disord. 2005 Dec;7(6):518-24 [16403177.001]
  • [Cites] J Child Adolesc Psychopharmacol. 2006 Aug;16(4):456-66 [16958570.001]
  • [Cites] Biol Psychiatry. 2006 Nov 1;60(9):903-11 [16650832.001]
  • [Cites] Biol Psychiatry. 2006 Nov 1;60(9):912-20 [16735031.001]
  • [Cites] Biol Psychiatry. 2006 Nov 1;60(9):991-7 [17056393.001]
  • [Cites] Biol Psychiatry. 2007 Jul 15;62(2):115-20 [16950211.001]
  • [Cites] Biol Psychiatry. 2007 Jul 15;62(2):129-34 [17481590.001]
  • [Cites] Am J Psychiatry. 2007 Aug;164(8):1140-2 [17671272.001]
  • [Cites] Bipolar Disord. 2007 Dec;9(8):895-900 [18076540.001]
  • [Cites] J Neural Transm (Vienna). 2008;115(2):155-61 [17994189.001]
  • [Cites] J Clin Psychiatry. 2007;68 Suppl 11:4-8 [18307375.001]
  • [Cites] Hum Psychopharmacol. 2008 Jun;23(4):291-9 [18421802.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 2008 Mar;47(3):273-81 [18216734.001]
  • [Cites] J Affect Disord. 2009 Mar;113(3):227-35 [18632161.001]
  • [Cites] J Child Adolesc Psychopharmacol. 2009 Feb;19(1):23-30 [19232020.001]
  • [Cites] J Child Psychol Psychiatry. 2009 Mar;50(3):216-23 [19166573.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 2009 Apr;48(4):404-12 [19318881.001]
  • [Cites] J Clin Psychiatry. 2009 May;70(5):732-40 [19389330.001]
  • [Cites] Am J Psychiatry. 2009 Jul;166(7):795-804 [19448190.001]
  • [Cites] Psychol Med. 2009 Aug;39(8):1237-45 [19079807.001]
  • [Cites] Arch Gen Psychiatry. 2009 Jul;66(7):764-72 [19581568.001]
  • [Cites] Soc Psychiatry Psychiatr Epidemiol. 2009 Sep;44(9):792-803 [19212695.001]
  • [Cites] Br J Psychiatry. 2009 Sep;195(3):249-56 [19721116.001]
  • [Cites] Am J Psychiatry. 2009 Sep;166(9):1048-54 [19570932.001]
  • [Cites] J Child Psychol Psychiatry. 2009 Oct;50(10):1291-300 [19486226.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 2008 Oct;47(10):1151-7 [18724256.001]
  • [Cites] J Affect Disord. 2010 Feb;121(1-2):184-8 [19564046.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 2010 Apr;49(4):302-5 [20410722.001]
  • [Cites] Psychiatry Res. 2010 Aug 15;178(3):550-5 [20510462.001]
  • [Cites] J Psychopharmacol. 2010 Sep;24(9):1317-32 [20007413.001]
  • [CommentIn] J Am Acad Child Adolesc Psychiatry. 2011 Sep;50(9):857-9 [21871367.001]
  • (PMID = 20970698.001).
  • [ISSN] 1527-5418
  • [Journal-full-title] Journal of the American Academy of Child and Adolescent Psychiatry
  • [ISO-abbreviation] J Am Acad Child Adolesc Psychiatry
  • [Language] ENG
  • [Grant] United States / NIMH NIH HHS / MH / K08 MH082116; United States / NIMH NIH HHS / MH / K08MH082116
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS229740; NLM/ PMC2965164
  •  go-up   go-down


95. Zepf FD, Wöckel L, Poustka F, Holtmann M: Diminished 5-HT functioning in CBCL pediatric bipolar disorder-profiled ADHD patients versus normal ADHD: susceptibility to rapid tryptophan depletion influences reaction time performance. Hum Psychopharmacol; 2008 Jun;23(4):291-9
Hazardous Substances Data Bank. (L)-Tryptophan .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diminished 5-HT functioning in CBCL pediatric bipolar disorder-profiled ADHD patients versus normal ADHD: susceptibility to rapid tryptophan depletion influences reaction time performance.
  • OBJECTIVE: There is a current debate on characterizing children with pediatric bipolar disorder (PBD) through a profile within the child behaviour checklist (CBCL), and on the involvement of the 5-HT system in the underlying neurobiological processes of PBD.
  • The aim of the present paper was to investigate reaction time performance in patients with CBCL-PBD and to discriminate ADHD from ADHD with CBCL-PBD with respect to diminished 5-HT functioning and reaction time.
  • The study sample was divided into high and low scorers according to their CBCL-PBD scores.
  • RESULTS: Comparing those six patients with the highest and clinically significant CBCL-PBD scores versus those six patients with the lowest, patients with a high CBCL-PBD score showed a slower reaction time under RTD compared to patients with low CBCL-PBD scores after high provocation.
  • CBCL-'aggression' discriminated between the two groups.
  • CONCLUSIONS: The results suggest alterations in 5-HT functioning in CBCL-PBD-spectrum patients, and 'aggression' as a potential moderator variable to ADHD.


96. Mao X, Orchard G, Russell-Jones R, Whittaker S: Abnormal activator protein 1 transcription factor expression in CD30-positive cutaneous large-cell lymphomas. Br J Dermatol; 2007 Nov;157(5):914-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abnormal activator protein 1 transcription factor expression in CD30-positive cutaneous large-cell lymphomas.
  • BACKGROUND: CD30+ cutaneous large-cell lymphomas (CLCL) represent a heterogeneous subgroup of skin lymphomas including primary cutaneous CD30+ anaplastic large-cell lymphoma (C-ALCL), lymphomatoid papulosis (LyP), transformed mycosis fungoides (T-MF) and Hodgkin's lymphoma (HL) with cutaneous involvement.
  • METHODS: We analysed paraffin tissue sections from 27 patients with LyP, 10 with C-ALCL, eight with T-MF and two with cutaneous HL by immunohistochemistry with antibodies against c-JUN, JUNB, JUND, c-FOS and RAF-1.
  • We also stained samples from 10 patients with C-ALCL, seven with Sézary syndrome (SS), six with T-MF, three with cutaneous HL, two with LyP and control samples with total and phosphorylated mitogen-activated protein kinase (MAPK) antibodies.
  • Results Positive staining for JUND (++) was observed in 13 cases of LyP (48%), 10 C-ALCL, six T-MF (75%) and two cutaneous HL cases.
  • Positive JUNB protein expression was present in four cases of T-MF (50%), four C-ALCL (44%), three LyP (11%) and two cutaneous HL.
  • Expression of total (p44/42) MAP kinase and phosphorylated p44/42 MAP kinase were detected in nine cases of C-ALCL (90%), seven SS (88%), five T-MF (89%) and three cutaneous HL.
  • [MeSH-major] Hodgkin Disease / metabolism. Lymphoma, T-Cell, Cutaneous / metabolism. Proto-Oncogene Proteins / metabolism. Skin Neoplasms / metabolism. Transcription Factor AP-1 / metabolism


97. Demarosi F, Soligo D, Lodi G, Moneghini L, Sardella A, Carrassi A: Squamous cell carcinoma of the oral cavity associated with graft versus host disease: report of a case and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2005 Jul;100(1):63-9
MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma of the oral cavity associated with graft versus host disease: report of a case and review of the literature.
  • Allogenic peripheral stem cell transplantation (HSCT), a procedure that is widely used in the treatment of a large number of malignant and nonmalignant hematological diseases, is still associated with a wide range of complications, one of the most important of which is graft-versus-host disease (GVHD).
  • Solid tumors are less frequent, but their incidence seems to be higher in the patients who develop GVHD; the most frequent solid tumors are squamous cell carcinomas.
  • We here describe the clinical course and histopathologic aspects of a squamous cell carcinoma arising on GVHD-induced oral lesions in a 53-year-old woman with non-Hodgkin's lymphoma undergoing allogeneic HSCT.
  • Immediately after the transplantation, the patient developed GVHD involving the gastroenteric tract, skin, joints, and oral cavity, which was treated with cyclosporin, prednisone, azathioprine, colchicine, and photophereses.
  • In addition to the sporadic reports of similar pictures published in the literature (16 cases of squamous cell carcinoma owing to oral GVHD in patients undergoing allogeneic HSCT), our case underlines the susceptibility of HSCT patients with oral GVHD to carcinoma of the oral cavity.
  • [MeSH-major] Bone Marrow Transplantation / adverse effects. Carcinoma, Squamous Cell / etiology. Gingival Neoplasms / etiology. Graft vs Host Disease / complications
  • [MeSH-minor] Female. Humans. Immunosuppressive Agents / adverse effects. Immunosuppressive Agents / therapeutic use. Lichen Planus, Oral / etiology. Lymphoma, Non-Hodgkin / therapy. Middle Aged. Transplantation Conditioning / adverse effects. Transplantation Immunology / physiology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Oral squamous cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15953918.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  • [Number-of-references] 26
  •  go-up   go-down


98. Hawk B, McCall RB: CBCL behavior problems of post-institutionalized international adoptees. Clin Child Fam Psychol Rev; 2010 Jun;13(2):199-211
MedlinePlus Health Information. consumer health - Child Behavior Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CBCL behavior problems of post-institutionalized international adoptees.
  • Generally, samples of post-institutional children have more problems than samples of mixed or non-institutional internationally adopted children, and some problems are more likely to be manifest in adolescence, suggesting the effects of deficient early experiences are not simply the persistence of learned behavior but more general dispositions that become more noticeable or severe during adolescence.

  • MedlinePlus Health Information. consumer health - Adoption.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Acad Child Adolesc Psychiatry. 1990 Jan;29(1):104-11 [2295561.001]
  • [Cites] J Dev Behav Pediatr. 2004 Jun;25(3):175-80 [15194902.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 1995 Feb;34(2):151-9 [7896648.001]
  • [Cites] J Abnorm Child Psychol. 1995 Oct;23(5):619-39 [8568084.001]
  • [Cites] Aust N Z J Psychiatry. 1996 Aug;30(4):534-9 [8887706.001]
  • [Cites] Child Dev. 1998 Aug;69(4):1092-106 [9768488.001]
  • [Cites] Child Psychiatry Hum Dev. 1999 Spring;29(3):221-8 [10080964.001]
  • [Cites] JAMA. 2005 May 25;293(20):2501-15 [15914751.001]
  • [Cites] Dev Psychopathol. 2007 Winter;19(1):129-48 [17241487.001]
  • [Cites] Dev Psychol. 2007 Jul;43(4):931-46 [17605526.001]
  • [Cites] Dev Psychopathol. 2008 Spring;20(2):547-67 [18423094.001]
  • [Cites] Monogr Soc Res Child Dev. 2008;73(3):vii-viii, 1-262, 294-5 [19121007.001]
  • [Cites] Child Dev. 2010 Jan-Feb;81(1):224-36 [20331664.001]
  • [Cites] J Abnorm Child Psychol. 2010 May;38(4):459-70 [20084451.001]
  • [Cites] J Child Psychol Psychiatry. 1999 Nov;40(8):1239-48 [10604402.001]
  • [Cites] J Child Psychol Psychiatry. 2000 Feb;41(2):139-49 [10750540.001]
  • [Cites] Child Psychiatry Hum Dev. 2000 Fall;31(1):79-96 [11033930.001]
  • [Cites] J Child Psychol Psychiatry. 2000 Nov;41(8):1025-37 [11099119.001]
  • [Cites] Br J Psychiatry. 2001 Aug;179:97-103 [11483469.001]
  • [Cites] Psychoneuroendocrinology. 2002 Jan-Feb;27(1-2):181-97 [11750778.001]
  • [Cites] Dev Psychopathol. 2002 Fall;14(4):843-60 [12549706.001]
  • [Cites] J Abnorm Psychol. 2003 May;112(2):179-92 [12784827.001]
  • [Cites] Dev Psychopathol. 2003 Fall;15(4):853-84 [14984130.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 1990 Jan;29(1):94-103 [2295584.001]
  • (PMID = 20514520.001).
  • [ISSN] 1573-2827
  • [Journal-full-title] Clinical child and family psychology review
  • [ISO-abbreviation] Clin Child Fam Psychol Rev
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / R01HD39017; United States / NICHD NIH HHS / HD / R01 HD050212-04; United States / NIMH NIH HHS / MH / R25MH5431813; United States / NICHD NIH HHS / HD / R01 HD050212; United States / NICHD NIH HHS / HD / R01 HD039017; None / None / / R01 HD050212-04; United States / NICHD NIH HHS / HD / R01HD50212
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS258763; NLM/ PMC3021319
  •  go-up   go-down


99. Hashino S, Morita L, Takahata M, Onozawa M, Nakagawa M, Kawamura T, Fujisawa F, Kahata K, Izumiyama K, Yonezumi M, Chiba K, Kondo T, Asaka M: Administration of micafungin as prophylactic antifungal therapy in patients undergoing allogeneic stem cell transplantation. Int J Hematol; 2008 Jan;87(1):91-7
Hazardous Substances Data Bank. FLUCONAZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Administration of micafungin as prophylactic antifungal therapy in patients undergoing allogeneic stem cell transplantation.
  • Invasive fungal infection is one of the major causes of death in neutropenic patients undergoing allogeneic stem cell transplantation (SCT).
  • Underlying diseases included acute leukemia (n = 16), non-Hodgkin's lymphoma (n = 11), myelodysplastic syndrome (n = 6), and others (n = 11) in the MCFG group and acute leukemia (n = 18), chronic myelogenous leukemia (n = 6), and others (n = 5) in the FLCZ group.
  • Although one patient in the MCFG group required the discontinuation of MCFG due to allergic skin eruption (grade 2), none of the other patients in either group required dose reduction due to adverse effects.
  • [MeSH-major] Antibiotic Prophylaxis. Antifungal Agents / therapeutic use. Echinocandins / therapeutic use. Hematopoietic Stem Cell Transplantation. Lipoproteins / therapeutic use. Mycoses / prevention & control

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biol Blood Marrow Transplant. 2004 Sep;10(9):645-52 [15319776.001]
  • [Cites] Br J Haematol. 2002 Apr;117(1):40-6 [11918531.001]
  • [Cites] J Infect Dis. 1995 Jun;171(6):1545-52 [7769290.001]
  • [Cites] Lancet. 2007 May 5;369(9572):1519-27 [17482982.001]
  • [Cites] Lancet. 2003 Oct 4;362(9390):1142-51 [14550704.001]
  • [Cites] Blood. 2003 Aug 1;102(3):827-33 [12689933.001]
  • [Cites] N Engl J Med. 1992 Mar 26;326(13):845-51 [1542320.001]
  • [Cites] Bone Marrow Transplant. 2006 Nov;38(10):693-8 [16980989.001]
  • [Cites] Intern Med. 2006;45(5):259-64 [16595990.001]
  • [Cites] Ann Intern Med. 2003 May 6;138(9):705-13 [12729424.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 Jul;13(7):771-7 [17580255.001]
  • [Cites] Clin Infect Dis. 2004 Nov 15;39(10):1407-16 [15546073.001]
  • [Cites] Antimicrob Agents Chemother. 1993 Sep;37(9):1847-9 [8239594.001]
  • [Cites] Expert Rev Anti Infect Ther. 2006 Jun;4(3):457-68 [16771622.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4358-66 [12393425.001]
  • [Cites] N Engl J Med. 1991 Oct 31;325(18):1274-7 [1669837.001]
  • [Cites] Blood. 2000 Sep 15;96(6):2055-61 [10979947.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1527-33 [14525770.001]
  • [Cites] J Infect Dis. 2004 Aug 1;190(3):641-9 [15243943.001]
  • (PMID = 18224421.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Echinocandins; 0 / Lipopeptides; 0 / Lipoproteins; 8VZV102JFY / Fluconazole; R10H71BSWG / micafungin
  •  go-up   go-down


100. Tan TX, Dedrick RF, Marfo K: Factor structure and clinical implications of child behavior checklist/1.5-5 ratings in a sample of girls adopted from China. J Pediatr Psychol; 2007 Aug;32(7):807-18
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: This study assessed psychometric properties of the Child Behavior Checklist (CBCL/1.5-5) and explored clinical insights from its use in a sample of adopted Chinese girls.
  • CONCLUSIONS: The study provides additional evidence of the factorial validity of the CBCL/1.5-5 and supports its use with Chinese girls adopted into North American families.
  • While the Chinese girls showed similar or better behavioral adjustment, compared to a reference group from the CBCL's normative sample, they tended to manifest higher levels of sleep problems.






Advertisement